Traumatic Brain Injury

Complex MONDO:0858950 Pathograph 28 Show in embeddings browser

Damage to the brain caused by an external mechanical force: a blow to the head, rapid acceleration and deceleration, penetration, or blast. The injury unfolds in two stages. The primary injury is mechanical and happens in milliseconds: tissue is deformed, vessels tear, and axons are stretched beyond their tolerance. A secondary injury cascade then develops over hours to days, driven by excitotoxic glutamate release, spreading depolarisations, blood-brain barrier disruption, cytotoxic brain swelling and raised intracranial pressure, and systemic insults such as hypotension and hypoxia. In a proportion of survivors a chronic phase follows, with neuroinflammation and white matter degeneration that persist for years and an increased risk of dementia. Severity ranges from concussion to coma, and it is graded clinically by the Glasgow Coma Scale and the duration of loss of consciousness and post-traumatic amnesia rather than by mechanism.

Ask OpenScientist

Ask a research question about Traumatic Brain Injury. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

11
Pathophys.
11
Phenotypes
3
Gaps
28
Pathograph
8
Medical Actions
3
Trials
1
Models
1
Deep Research
?

Discussions and Knowledge Gaps

3
Why have neuroprotective agents that work robustly in animal models of traumatic brain injury, progesterone most prominently, failed in large phase 3 trials?
HUMAN MODEL MISMATCH OPEN tbi_neuroprotection_translation_failure
Attached to
pathophysiology#Secondary Neuronal Loss clinical_trials#NCT00822900 clinical_trials#NCT01143064
The secondary injury cascade was mapped mostly in rodent models, where single interventions given at a controlled time after a reproducible injury protect tissue. Two independent phase 3 trials of progesterone, and earlier trials of other agents, found no benefit in patients. Candidate explanations bear directly on the model: human injuries combine focal and diffuse lesions in varying proportions, which the rodent injury models do not; treatment is given later and less uniformly; and dichotomised functional outcome scales may miss real but modest effects. Until one of these is shown to account for the failures, the rodent evidence for any single node of the secondary cascade should not be read as evidence that it is a tractable human target.
Show evidence (1 reference)
PMID:25493978 SUPPORT Human Clinical
"These data stand in contrast to the robust preclinical data and results of early single-center trials that provided the impetus to initiate phase 3 trials."
The trial authors state the mismatch between preclinical and phase 3 results directly.
Does blood-brain barrier disruption that persists for years after a single injury contribute to late neurodegeneration and dementia, or is it a marker of damage that has already happened?
KNOWLEDGE GAP OPEN tbi_persistent_barrier_disruption_and_neurodegeneration
Attached to
pathophysiology#Blood-Brain Barrier Disruption phenotypes#Dementia
Autopsy evidence shows barrier leakage in nearly half of long-term survivors of a single moderate or severe injury, and a single injury raises dementia risk. Barrier dysfunction is implicated in other dementias. No study links the two in the same patients, so the entry draws no edge from barrier disruption to dementia.
Show evidence (1 reference)
PMID:26574669 SUPPORT Human Clinical
"These preliminary data demonstrate evidence of widespread BBB disruption in a proportion of TBI patients emerging in the acute phase and, intriguingly, persisting in a high proportion of late survivors."
Documents the persistence that motivates the question.
Is the chronic microglial activation seen years after injury a response to ongoing white matter degeneration, or does it drive that degeneration?
KNOWLEDGE GAP OPEN tbi_inflammation_white_matter_direction
Attached to
pathophysiology#Persistent Neuroinflammation pathophysiology#White Matter Degeneration and Circuit Disconnection
The two co-occur in the same cases, and the entry draws an indirect edge from inflammation to white matter degeneration because that is the direction a therapy would exploit. The source study states explicitly that the direction is undetermined. If inflammation is a response, targeting it would not slow degeneration.
Show evidence (1 reference)
PMID:23365092 SUPPORT Human Clinical
"Future studies to determine whether inflammation occurs in response to or, conversely, promotes white matter degeneration will be important."
The authors state the open question.
⚙

Pathophysiology

11
Rapid Head Acceleration and Brain Tissue Deformation
The primary, mechanical injury. Impact or inertial loading of the head deforms brain tissue within milliseconds. Axons, which are viscoelastic and tolerate slow stretch, fail under rapid deformation, and strain concentrates at predictable sites such as the depths of cortical sulci and the grey-white matter boundary. Where the load tears vessels or bruises cortex the result is a focal lesion; where it shears white matter tracts the result is diffuse axonal injury.
brain UBERON:0000955 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in brain (UBERON:0000955). UBERON:0000955 is an anatomical location from the Uberon multi-species anatomy ontology.
Computational models
Finite-Element Head Model of Brain Injury Biomechanics BIOMECHANICAL The model computes the tissue deformation this node describes, for reconstructed real-world impacts.
Downstream
Focal Contusion and Intracranial Haemorrhage Where the load bruises cortex or tears bridging and parenchymal vessels, the primary injury produces contusions and intracranial haematomas.
Diffuse Axonal Injury Shear and stretch of white matter tracts during rapid acceleration damages the axonal cytoskeleton.
Blood-Brain Barrier Disruption The injury disrupts the blood-brain barrier, documented in human brain tissue from the acute phase onward.
Show evidence (2 references)
PMID:16222127 SUPPORT Other
"Although axons are supple under normal conditions, they become brittle when exposed to rapid deformations associated with brain trauma."
States the biomechanical basis of the primary injury: axonal tolerance depends on loading rate, which is why rapid head acceleration injures axons.
PMID:28043957 SUPPORT Computational
"The computational models predicted large strain most prominent at the depths of sulci."
A finite-element head model shows that tissue deformation is not uniform but concentrates at the depths of sulci.
Focal Contusion and Intracranial Haemorrhage
Cortical contusions and extra-axial (subdural, epidural) or intraparenchymal haematomas. Bleeding can continue and expand for hours after the impact, which is the basis for early antifibrinolytic treatment, and an expanding mass raises intracranial pressure and can cause herniation.
cerebral cortex UBERON:0000956 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in cerebral cortex (UBERON:0000956). UBERON:0000956 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Cerebral Contusion The cortical bruise is the clinical and imaging form of this node.
Subdural Hemorrhage Tearing of bridging veins produces the subdural haematoma, one of the haemorrhages this node covers.
Intracranial Hemorrhage Intracranial bleeding is the clinical form of this node.
Excitotoxic Glutamate Release Extracellular glutamate rises most in patients with focal contusions and secondary ischaemia.
Spreading Depolarisations Spreading depolarisations arise in injured grey matter, typically around contusions in patients who need surgery.
Cytotoxic Brain Swelling and Raised Intracranial Pressure Expanding haematoma adds intracranial volume and can cause herniation.
Show evidence (1 reference)
PMID:31623894 SUPPORT Human Clinical
"Intracranial bleeding is common after traumatic brain injury (TBI) and can cause brain herniation and death."
Establishes intracranial bleeding as a common and lethal component of the injury.
Diffuse Axonal Injury
Multifocal injury to axons in the cerebral white matter, corpus callosum and brainstem caused by inertial shear. Damaged axons lose transport, swell into varicosities and bulbs that accumulate transported proteins, and may later disconnect; current understanding treats most disconnection as a delayed, biochemically driven secondary axotomy rather than immediate tearing. It is a principal determinant of loss of consciousness and of long-term outcome, and it is hard to see on conventional imaging. In this entry the node is the trauma-specific instance of the module's focal axonal injury trigger.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
response to axon injury GO:0048678 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves response to axon injury (GO:0048678). GO:0048678 is a biological process from the Gene Ontology.
cerebral white matter UBERON:0002437 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in cerebral white matter, annotated with cerebral hemisphere white matter (UBERON:0002437). UBERON:0002437 is an anatomical location from the Uberon multi-species anatomy ontology. corpus callosum UBERON:0002336 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in corpus callosum (UBERON:0002336). UBERON:0002336 is an anatomical location from the Uberon multi-species anatomy ontology.
Computational models
Finite-Element Head Model of Brain Injury Biomechanics BIOMECHANICAL High-strain regions predicted by the model coincide with white matter abnormality on patient imaging and, in the rat version, with axonal and glial injury on histology.
Downstream
White Matter Degeneration and Circuit Disconnection Swollen axons disconnect and degenerate, and white matter is lost over the following months and years.
Loss of Consciousness Diffuse axonal injury is thought to account for much of the clinical deficit after closed head injury, including loss of consciousness; it was historically defined clinically by prolonged unconsciousness without a mass lesion.
Coma Widespread axonal injury disconnects the networks that sustain arousal, and prolonged unconsciousness without a mass lesion was the original clinical definition of diffuse axonal injury.
Show evidence (3 references)
PMID:2767623 SUPPORT Human Clinical
"Diffuse axonal injury was identified in 122 of a series of 434 fatal non-missile head injuries"
Neuropathological series establishing diffuse axonal injury as common in fatal closed head injury.
PMID:16222127 SUPPORT Other
"Subsequent swelling of the axon occurs in discrete bulb formations or in elongated varicosities that accumulate transported proteins."
Describes the transport failure and axonal swelling that follow the mechanical insult.
PMID:33006648 SUPPORT Other
"This theory has now been partially abandoned in favor of a more refined theory involving biochemical processes such as protein cleavage and DNA breakdown, ultimately leading to an inflammation cascade and cell apoptosis, a process now described as secondary axotomy."
Supports treating axonal disconnection as a delayed biochemical process rather than immediate mechanical tearing, which is what the module models.
Blood-Brain Barrier Disruption
Leakage of plasma proteins such as fibrinogen and immunoglobulin G into the brain parenchyma, seen in a proportion of patients from the acute phase and, strikingly, in a similar proportion of survivors examined years after a single injury. Whether this persistent leakage drives late neurodegeneration is open.
cerebral cortex UBERON:0000956 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in cerebral cortex (UBERON:0000956). UBERON:0000956 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (1 reference)
PMID:26574669 SUPPORT Human Clinical
"After TBI, 40% of patients dying in the acute phase and 47% of those surviving a year or more from injury showed multifocal, abnormal, perivascular, and parenchymal fibrinogen and immunoglobulin G immunostaining localized to the gray matter"
Quantifies barrier disruption in the acute phase and its persistence in long-term survivors.
Excitotoxic Glutamate Release
Extracellular glutamate and other excitatory amino acids rise to many times normal in a subset of severely injured patients, most in those with contusions or secondary ischaemia, and high levels track raised intracranial pressure and poor outcome. The release correlates with structural amino acids, which suggests it reflects membrane damage as much as vesicular release.
glutamate secretion GO:0014047 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves glutamate secretion (GO:0014047). GO:0014047 is a biological process from the Gene Ontology.
Downstream
Secondary Neuronal Loss Glutamate excess drives calcium overload and excitotoxic neuronal death, the cascade modelled in glutamate_excitotoxicity.
Show evidence (1 reference)
PMID:9761042 SUPPORT Human Clinical
"The levels of EAAs were increased up to 50 times normal in 30% of the patients"
Direct microdialysis measurement of excitatory amino acid release in severely head-injured patients.
Spreading Depolarisations
Waves of near-complete neuronal and glial depolarisation that propagate slowly through injured cortex, recorded by electrocorticography in about half of patients undergoing surgery for TBI. Their occurrence, especially in electrically silent cortex, independently predicts unfavourable outcome. No GO term describes a spreading depolarisation, so the node carries no process binding.
cerebral cortex UBERON:0000956 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in cerebral cortex (UBERON:0000956). UBERON:0000956 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Secondary Neuronal Loss Repeated depolarisations in metabolically compromised cortex are thought to extend the lesion. The cited study shows association with outcome, not neuronal death directly.
Show evidence (1 reference)
PMID:22056157 SUPPORT Human Clinical
"Spreading depolarisations were associated with unfavourable outcome, after controlling for conventional prognostic variables."
Independent association of spreading depolarisations with poor outcome in a prospective multicentre cohort.
Secondary Systemic Insults (Hypotension and Hypoxia)
Arterial hypotension and hypoxaemia occurring between injury and the end of resuscitation. They are common, independently associated with worse mortality and morbidity, and the main preventable contributors to secondary ischaemic brain damage.
Downstream
Secondary Neuronal Loss Systemic hypotension and hypoxia reduce oxygen delivery to injured brain and add ischaemic damage.
Show evidence (1 reference)
PMID:8459458 SUPPORT Human Clinical
"Hypotension was profoundly detrimental, occurring in 34.6% of these patients and associated with a 150% increase in mortality."
Traumatic Coma Data Bank analysis quantifying the frequency and impact of hypotension after severe head injury.
Cytotoxic Brain Swelling and Raised Intracranial Pressure
Brain swelling after severe injury, measured by diffusion MRI in patients, is predominantly cellular rather than vasogenic, and it occurs in tissue whose blood flow is above the ischaemic range. Swelling and mass lesions together raise intracranial pressure, which when refractory is lethal and is the target of tiered medical treatment and decompressive craniectomy.
brain UBERON:0000955 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in brain (UBERON:0000955). UBERON:0000955 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Increased Intracranial Pressure Brain swelling raises intracranial pressure.
Show evidence (2 references)
PMID:16703876 SUPPORT Human Clinical
"The brain swelling observed in patients with TBI appears to be predominantly cellular, as signaled by low ADC values in brain tissue with high levels of water content."
Diffusion MRI in severely injured patients identifies the swelling as cellular rather than vasogenic.
PMID:16671417 SUPPORT Human Clinical
"it is concluded that the predominant form of edema responsible for brain swelling and raised ICP is cellular in nature"
Links the cellular edema directly to raised intracranial pressure.
Secondary Neuronal Loss
Death of neurons beyond the primary lesion during the hours and days after injury, to which excitotoxicity, spreading depolarisations and systemic ischaemic insults all contribute. It is the stage that neuroprotective drug trials have tried, so far unsuccessfully, to prevent.
neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Downstream
Cognitive impairment Loss of neurons and circuits underlies persisting cognitive deficits.
Show evidence (1 reference)
PMID:9761042 SUPPORT INDIRECT Human Clinical
"Sustained high ICP and poor outcome were significantly correlated to high levels of EAAs"
Secondary injury markers track poor outcome; neuronal death is the presumed intermediate and was not measured directly.
Persistent Neuroinflammation
Dense reactive microglia in the white matter that are absent acutely but appear by three months and persist for up to 18 years in about a quarter of long-term survivors of a single injury. Whether this inflammation is a response to ongoing white matter degeneration or a driver of it is unresolved.
microglial cell CL:0000129 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves microglial cell (CL:0000129). CL:0000129 is a cell type from the Cell Ontology.
microglial cell activation GO:0001774 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves microglial cell activation (GO:0001774). GO:0001774 is a biological process from the Gene Ontology. neuroinflammatory response GO:0150076 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves neuroinflammatory response (GO:0150076). GO:0150076 is a biological process from the Gene Ontology.
corpus callosum UBERON:0002336 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in corpus callosum (UBERON:0002336). UBERON:0002336 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
White Matter Degeneration and Circuit Disconnection Persistent inflammation co-localises with ongoing white matter degradation. The direction of causation is not established, which this entry records as a knowledge gap.
Show evidence (1 reference)
PMID:23365092 SUPPORT Human Clinical
"these reactive microglia were present in 28% of cases with survival of >1 year and up to 18 years post-trauma"
Autopsy evidence of microglial activation persisting for years after a single injury.
White Matter Degeneration and Circuit Disconnection
Progressive loss of white matter after the injury, measurable as thinning of the corpus callosum in long-term survivors, which disconnects cortical networks. It is the structural substrate proposed for persisting cognitive deficits and for the increased risk of late neurodegeneration.
corpus callosum UBERON:0002336 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in corpus callosum (UBERON:0002336). UBERON:0002336 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Cognitive impairment Disconnection of white matter networks is the proposed substrate of persisting cognitive deficits.
Dementia Long-term white matter degeneration and inflammation are proposed links between a single injury and later dementia.
Show evidence (1 reference)
PMID:23365092 SUPPORT Human Clinical
"there was a 25% reduction in the corpus callosum thickness with survival >1 year post-injury"
Quantifies white matter loss in long-term survivors.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Traumatic Brain Injury Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

11
Blood 2
Subdural Hemorrhage HP:0100309 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Subdural hematoma, annotated with Subdural hemorrhage (HP:0100309). HP:0100309 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:9414327 SUPPORT Human Clinical
"severe (loss of consciousness or amnesia for more than 24 hours, subdural hematoma, or brain contusion)"
Subdural haematoma is a defining lesion of severe injury.
Intracranial Hemorrhage HP:0002170 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intracranial hemorrhage (HP:0002170), qualified as temporality acute. HP:0002170 is a phenotype from the Human Phenotype Ontology.
Temporal: ACUTE
Show evidence (1 reference)
PMID:31623894 SUPPORT Human Clinical
"Intracranial bleeding is common after traumatic brain injury (TBI)"
Intracranial bleeding is a common feature of the injury.
Nervous System 9
Loss of Consciousness HP:0007185 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Loss of consciousness (HP:0007185), qualified as temporality acute. HP:0007185 is a phenotype from the Human Phenotype Ontology.
Temporal: ACUTE
Show evidence (1 reference)
PMID:9414327 SUPPORT Human Clinical
"Injuries were classified as mild (loss of consciousness or amnesia lasting less than 30 minutes), moderate (loss of consciousness for 30 minutes to 24 hours or a skull fracture)"
Loss of consciousness is the feature by which injury severity is graded.
Coma HP:0001259 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Coma (HP:0001259), qualified as temporality acute. HP:0001259 is a phenotype from the Human Phenotype Ontology.
Temporal: ACUTE
Show evidence (1 reference)
PMID:25493978 SUPPORT Human Clinical
"with severe TBI (Glasgow Coma Scale score, ≤8"
Uses the coma-range Glasgow Coma Scale score as the definition of severe injury.
Post-Traumatic Amnesia Memory impairment HP:0002354 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Post-traumatic amnesia, annotated with Memory impairment (HP:0002354), qualified as temporality acute. HP:0002354 is a phenotype from the Human Phenotype Ontology.
Temporal: ACUTE
Show evidence (1 reference)
PMID:9414327 SUPPORT Human Clinical
"Injuries were classified as mild (loss of consciousness or amnesia lasting less than 30 minutes)"
Amnesia duration is one of the two clinical features used to grade severity.
Cerebral Contusion HP:6000141 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebral contusion (HP:6000141). HP:6000141 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:9414327 SUPPORT Human Clinical
"severe (loss of consciousness or amnesia for more than 24 hours, subdural hematoma, or brain contusion)"
Brain contusion is a defining lesion of severe injury.
Increased Intracranial Pressure HP:0002516 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Increased intracranial pressure (HP:0002516), qualified as temporality acute. HP:0002516 is a phenotype from the Human Phenotype Ontology.
Temporal: ACUTE
Show evidence (1 reference)
PMID:27602507 SUPPORT Human Clinical
"with traumatic brain injury and refractory elevated intracranial pressure (>25 mm Hg)"
Refractory intracranial hypertension after TBI is common enough to define the population of a 408-patient trial.
Headache HP:0002315 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Post-traumatic headache, annotated with Headache (HP:0002315). HP:0002315 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:21732765 SUPPORT Human Clinical
"71% of participants reported headache during the first year after injury"
Prospective cohort quantifying post-traumatic headache.
Cognitive impairment HP:0100543 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cognitive impairment (HP:0100543), qualified as temporality chronic. HP:0100543 is a phenotype from the Human Phenotype Ontology.
Temporal: CHRONIC
Show evidence (1 reference)
PMID:35173018 SUPPORT Human Clinical
"At 1 year, 13.5% of participants with mTBI had a poor cognitive outcome vs 4.5% of controls (p = 0.003)."
Poor cognitive outcome is three times as common after mild injury as in controls.
Early Post-Traumatic Seizures HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Early post-traumatic seizure, annotated with Seizure (HP:0001250), qualified as temporality acute. HP:0001250 is a phenotype from the Human Phenotype Ontology.
Temporal: ACUTE
Show evidence (1 reference)
PMID:2115976 SUPPORT Human Clinical
"Between drug loading and day 7, 3.6 percent of the patients assigned to phenytoin had seizures, as compared with 14.2 percent of patients assigned to placebo"
Early seizures occur in about one in seven untreated patients after severe injury.
Dementia HP:0000726 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dementia (HP:0000726). HP:0000726 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:29653873 SUPPORT Human Clinical
"TBI was associated with an increased risk of dementia both compared with people without a history of TBI and with people with non-TBI trauma."
Nationwide cohort of 2.8 million people showing an increased dementia risk after TBI, also against a non-head trauma comparison group.
💊

Medical Actions

8
Tranexamic Acid
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: tranexamic acid CHEBI:48669 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses tranexamic acid (CHEBI:48669). CHEBI:48669 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Antifibrinolytic given within three hours of injury to limit expansion of intracranial bleeding. In the CRASH-3 trial it reduced head injury-related death in mild-to-moderate injury but not in severe injury, and earlier treatment was more effective.
Mechanism Target:
INHIBITS Focal Contusion and Intracranial Haemorrhage — Limits continued intracranial bleeding by inhibiting fibrinolysis.
Show evidence (1 reference)
PMID:31623894 SUPPORT Human Clinical
"Our results show that tranexamic acid is safe in patients with TBI and that treatment within 3 h of injury reduces head injury-related death."
Randomised evidence of benefit from early antifibrinolytic treatment.
Decompressive Craniectomy
Action: Decompressive craniectomyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Decompressive craniectomy, annotated with Craniectomy (NCIT:C51791). NCIT:C51791 is a clinical intervention from the NCI Thesaurus. Ontology label: Craniectomy NCIT:C51791
Platform: Surgery
Removal of part of the skull to relieve refractory intracranial hypertension. It lowers pressure reliably; its effect on outcome depends on the setting. As a last-tier treatment for refractory pressure it reduced mortality but left more survivors in a vegetative state or severely disabled, and used early in diffuse injury it worsened functional outcome.
Mechanism Target:
BYPASSES Cytotoxic Brain Swelling and Raised Intracranial Pressure — Relieves the pressure by enlarging the intracranial space rather than by reducing the swelling itself.
Show evidence (2 references)
PMID:27602507 SUPPORT Human Clinical
"At 6 months, decompressive craniectomy in patients with traumatic brain injury and refractory intracranial hypertension resulted in lower mortality and higher rates of vegetative state, lower severe disability, and upper severe disability than medical care."
Supports a mortality benefit as last-tier treatment, at the cost of more severely disabled survivors.
PMID:21434843 REFUTE Human Clinical
"early bifrontotemporoparietal decompressive craniectomy decreased intracranial pressure and the length of stay in the ICU but was associated with more unfavorable outcomes"
Used early in diffuse injury, the operation lowered pressure but worsened functional outcome, so it is not a general benefit.
Corticosteroids
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: methylprednisolone CHEBI:6888 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses methylprednisolone, annotated with 6alpha-methylprednisolone (CHEBI:6888). CHEBI:6888 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Not recommended. High-dose methylprednisolone was given for decades on the rationale of reducing brain swelling and inflammation; in the 10,008-patient CRASH trial it increased death within two weeks.
Show evidence (1 reference)
PMID:15474134 REFUTE Human Clinical
"Compared with placebo, the risk of death from all causes within 2 weeks was higher in the group allocated corticosteroids (1052 [21.1%] vs 893 [17.9%] deaths; relative risk 1.18 [95% CI 1.09-1.27]; p=0.0001)."
Refutes benefit: in a 10,008-patient randomised trial, two-week mortality was higher on corticosteroids than on placebo.
Early Seizure Prophylaxis
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: phenytoin CHEBI:8107 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses phenytoin (CHEBI:8107). CHEBI:8107 is a therapeutic agent from Chemical Entities of Biological Interest. levetiracetam CHEBI:6437 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses levetiracetam (CHEBI:6437). CHEBI:6437 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Phenytoin, or in current practice levetiracetam, given for about a week after severe injury. In the pivotal randomised trial it cut seizures in the first week from 14.2 to 3.6 percent but did not reduce later seizures, so it suppresses early provoked seizures and does not prevent post-traumatic epilepsy. The epilepsy is curated separately as Post-Traumatic_Epilepsy.
Target Phenotypes: Early post-traumatic seizure HP:0001250 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Early post-traumatic seizure, annotated with Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:2115976 SUPPORT Human Clinical
"Phenytoin exerts a beneficial effect by reducing seizures only during the first week after severe head injury."
Randomised evidence that prophylaxis reduces early seizures, and only early seizures.
PMID:2115976 REFUTE Human Clinical
"Between day 8 and the end of year 1, 21.5 percent of the phenytoin group and 15.7 percent of the placebo group had seizures"
Refutes any effect on late seizures, which is why prophylaxis is not continued to prevent epilepsy.
Hyperosmolar Therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: mannitol CHEBI:29864 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses mannitol (CHEBI:29864). CHEBI:29864 is a therapeutic agent from Chemical Entities of Biological Interest. hypertonic saline CHEBI:26710 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses hypertonic saline, annotated with sodium chloride (CHEBI:26710). CHEBI:26710 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Mannitol or hypertonic saline given to lower raised intracranial pressure, in routine use in moderate to severe injury. Randomised evidence has not shown that either agent improves functional outcome or survival, or that one is better than the other, and continuous prophylactic hypertonic saline did not improve six-month neurological outcome.
Mechanism Target:
INHIBITS Cytotoxic Brain Swelling and Raised Intracranial Pressure — Draws water from brain tissue into the circulation to lower intracranial pressure.
Show evidence (3 references)
PMID:37380894 SUPPORT BACKGROUND Other
"Hyperosmolar therapies, such as hypertonic saline (HTS) and mannitol, are in routine clinical use for lowering ICP in TBI."
Establishes hyperosmolar therapy as standard treatment for raised intracranial pressure in TBI.
PMID:37380894 REFUTE Other
"We found no evidence of an effect of HTS on clinically important outcomes and that HTS is associated with adverse hypernatremia."
Meta-analysis of ten randomised trials finding no outcome benefit of hypertonic saline over other pressure-lowering agents.
PMID:34032829 REFUTE Human Clinical
"treatment with continuous infusion of 20% hypertonic saline compared with standard care did not result in a significantly better neurological status at 6 months"
Prophylactic continuous hypertonic saline did not improve outcome in a 370-patient randomised trial.
Haematoma Evacuation
Action: Craniotomy for haematoma evacuationNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Craniotomy for haematoma evacuation, annotated with Craniotomy (NCIT:C15214). NCIT:C15214 is a clinical intervention from the NCI Thesaurus. Ontology label: Craniotomy NCIT:C15214
Platform: Surgery
Craniotomy to remove a space-occupying haematoma. Prompt removal of a significant subdural or extradural haematoma is established practice. For traumatic intraparenchymal haemorrhage the benefit of early surgery is uncertain: the only randomised trial, stopped early, found fewer deaths with early surgery but a non-significant difference in unfavourable outcome.
Mechanism Target:
INHIBITS Focal Contusion and Intracranial Haemorrhage — Removes the haematoma and its mass effect.
Show evidence (2 references)
PMID:25738794 SUPPORT BACKGROUND Other
"Prompt surgical removal of significant subdural (SDH) and extradural hemorrhage (EDH) is well established"
States that evacuation of significant extra-axial haematomas is established practice.
PMID:25738794 SUPPORT Human Clinical
"There were significantly more deaths in the first 6 months in the initial conservative treatment group (33% vs. 15%; p=0.006)."
Randomised evidence of lower mortality with early surgery for traumatic intraparenchymal haemorrhage, from a trial stopped early.
Therapeutic Hypothermia
Action: Therapeutic hypothermiaNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Therapeutic hypothermia, annotated with Induction and Maintenance of Total Body Hypothermia (NCIT:C219994). NCIT:C219994 is a clinical intervention from the NCI Thesaurus. Ontology label: Induction and Maintenance of Total Body Hypothermia NCIT:C219994
Platform: Other
Cooling to 32-35 degrees Celsius to lower intracranial pressure. It lowers pressure but did not improve outcome, and functional outcome was worse than with standard care in the Eurotherm3235 trial.
Show evidence (1 reference)
PMID:26444221 REFUTE Human Clinical
"therapeutic hypothermia plus standard care to reduce intracranial pressure did not result in outcomes better than those with standard care alone"
Refutes a functional benefit of hypothermia for raised pressure.
Amantadine
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: amantadine CHEBI:2618 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses amantadine (CHEBI:2618). CHEBI:2618 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Given during rehabilitation to patients in a vegetative or minimally conscious state weeks after injury. In a 184-patient randomised trial it accelerated functional recovery during four weeks of treatment, but the advantage was not sustained after the drug was stopped. It acts on recovery of function rather than on any injury mechanism in this entry, so it carries no target_mechanisms link.
Target Phenotypes: Coma HP:0001259 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Coma (HP:0001259). HP:0001259 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:22375973 SUPPORT Human Clinical
"Amantadine accelerated the pace of functional recovery during active treatment in patients with post-traumatic disorders of consciousness."
Randomised evidence that amantadine speeds recovery from prolonged post-traumatic disorders of consciousness while it is given.
PMID:22375973 REFUTE Human Clinical
"The overall improvement in DRS scores between baseline and week 6 (2 weeks after treatment was discontinued) was similar in the two groups."
Contradicts a lasting benefit: by two weeks after stopping the drug, the two groups had improved by the same amount.
🌍

Environmental Factors

1
Mechanical Head Trauma
No exposure_term. ECTO has no mechanical or traumatic injury exposure class; the searches are listed in the entry-level notes.
An external mechanical force to the head: impact, rapid acceleration and deceleration, penetration, or blast. Falls predominate in high-income countries, particularly in people aged 65 and over, and road traffic incidents in low- and middle-income countries. Severity is graded by the clinical picture rather than by the force, which is rarely measured.
Show evidence (2 references)
PMID:36183712 SUPPORT Other
"In HICs, most TBI is caused by falls, particularly in older people (aged ≥65 years), who often have comorbidities."
Identifies falls as the main cause in high-income countries.
PMID:36183712 SUPPORT Other
"In LMICs, the occurrence of TBI is driven by road traffic incidents"
Identifies road traffic incidents as the main cause in low- and middle-income countries.
Mechanism Target:
TRIGGERS Rapid Head Acceleration and Brain Tissue Deformation — The external force is what deforms the brain; it is the initiating event of every downstream process in this entry.
Show evidence (1 reference)
PMID:33454735 SUPPORT BACKGROUND Other
"White matter tracts are damaged by high shear forces during impact, resulting in axonal injury"
States that the impact force produces the tissue shear that injures white matter.
🔬

Biochemical Markers

2
Serum GFAP (INCREASED)
Context: Astroglial protein released into blood after brain injury. Measured within 12 hours together with UCH-L1, a negative combined result rules out CT-visible intracranial injury with high sensitivity in patients with a Glasgow Coma Scale score of 9-15. The combined test is used to avoid CT, not to diagnose injury.
Show evidence (1 reference)
PMID:30054151 SUPPORT Human Clinical
"These results show the high sensitivity and NPV of the UCH-L1 and GFAP test."
Validates the two-marker blood test, of which GFAP is one component, for ruling out CT-visible injury.
Serum UCH-L1 (INCREASED)
Context: Neuronal protein released into blood after brain injury; the second component of the combined GFAP and UCH-L1 test used to rule out CT-visible injury.
Show evidence (1 reference)
PMID:30054151 SUPPORT Human Clinical
"These results show the high sensitivity and NPV of the UCH-L1 and GFAP test."
Validates the two-marker blood test, of which UCH-L1 is one component, for ruling out CT-visible injury.
🔬

Diagnosis

1
Head CT
Non-contrast CT is the first-line test to detect haemorrhage, contusion and mass effect needing surgery. It is insensitive to diffuse axonal injury.
Computed tomography of the head NCIT:C17204 NCI Thesaurus (NCIT)
Show evidence (1 reference)
PMID:30054151 SUPPORT Human Clinical
"Detection of intracranial injuries relies on head CT, which is overused and resource intensive."
Establishes head CT as the reference test for intracranial injury.
📈

Progression

3
Primary injury
Age: Milliseconds to minutes after impact
Mechanical deformation of brain tissue, vessel tearing and axonal stretch. Nothing done after the event can reverse it; prevention (helmets, fall and road safety) is the only intervention at this phase.
Show evidence (1 reference)
PMID:16222127 SUPPORT Other
"they become brittle when exposed to rapid deformations associated with brain trauma"
The primary injury is the mechanical failure of tissue at impact.
Secondary injury
Age: Hours to days after injury
Expanding haemorrhage, excitotoxicity, spreading depolarisations, brain swelling with raised intracranial pressure, and systemic hypotension and hypoxia. This is the phase that acute care tries to limit.
Show evidence (1 reference)
PMID:8459458 SUPPORT Human Clinical
"Hypoxia and hypotension are common and detrimental secondary brain insults."
Characterises the preventable secondary insults of this phase.
Chronic phase
Age: Months to decades after injury
Persistent neuroinflammation, white matter degeneration and, in some survivors, barrier leakage, with persisting symptoms and an increased risk of dementia. The 2022 Lancet Neurology Commission describes TBI as a chronic disease as well as an acute condition.
Show evidence (2 references)
PMID:36183712 SUPPORT Other
"TBI is increasingly documented not only as an acute condition but also as a chronic disease with long-term consequences, including an increased risk of late-onset neurodegeneration."
Supports a distinct chronic phase.
PMID:23365092 SUPPORT Human Clinical
"These data present striking evidence of persistent inflammation and ongoing white matter degeneration for many years after just a single traumatic brain injury in humans."
Tissue evidence for an active chronic phase.
📊

Prevalence

2
Worldwide
Annual Incidence
A modelled estimate of 69 million (95% CI 64-74 million) new cases each year from all causes. The source gives regional rates but not a single worldwide rate per 100,000, so none is asserted here.
Show evidence (1 reference)
PMID:29701556 SUPPORT Human Clinical
"Sixty-nine million (95% CI 64-74 million) individuals worldwide are estimated to sustain a TBI each year."
Global annual incidence estimate.
North America (WHO region), modelled estimate
Annual Incidence 1299 per 100,000 (650–1947) per year >1 in 1,000 per year
The highest regional incidence in the source, 1299 per 100,000 per year; the source notes that regional rates are highest where data quality is highest, so the regional ranking partly reflects ascertainment.
Show evidence (1 reference)
PMID:29701556 SUPPORT Human Clinical
"The overall incidence of TBI per 100,000 people was greatest in North America (1299 cases, 95% CI 650-1947)"
Regional annual incidence per 100,000.
🔬

Clinical Trials

3
NCT00822900 PHASE_III TERMINATED
ProTECT III. Intravenous progesterone within 4 hours of moderate to severe injury, stopped for futility. With SyNAPSe it ended the progesterone neuroprotection programme despite strong preclinical data.
Show evidence (1 reference)
PMID:25493974 REFUTE Human Clinical
"This clinical trial did not show a benefit of progesterone over placebo in the improvement of outcomes in patients with acute TBI."
Negative phase 3 result for a neuroprotective agent.
NCT01143064 PHASE_III COMPLETED
SyNAPSe. Progesterone for severe injury in 1195 patients; no effect on outcome.
Show evidence (1 reference)
PMID:25493978 REFUTE Human Clinical
"Primary and secondary efficacy analyses showed no clinical benefit of progesterone in patients with severe TBI."
Negative phase 3 result for a neuroprotective agent.
NCT01068522 NOT_APPLICABLE COMPLETED
BEST-TRIP. Management guided by monitored intracranial pressure was not superior to management guided by imaging and clinical examination.
Show evidence (1 reference)
PMID:23234472 SUPPORT Human Clinical
"care focused on maintaining monitored intracranial pressure at 20 mm Hg or less was not shown to be superior to care based on imaging and clinical examination"
Questions whether a pressure threshold is the right treatment target.
🧮

Computational Models

1
Finite-Element Head Model of Brain Injury Biomechanics finite-element mesh BIOMECHANICAL
A high-fidelity three-dimensional finite-element model of the human head that computes strain and strain rate in brain tissue for a given head loading. Applied to a helmet-to-helmet American football impact, a fall and a road traffic collision, it predicts that strain concentrates at the depths of sulci, and patient diffusion tensor imaging shows abnormalities in the same sulcal regions. A rat version of the model was later validated against histology after controlled cortical impact.
PMID:28043957
Pathograph links
Rapid Head Acceleration and Brain Tissue Deformation recapitulates fidelity: moderate observes: tissue The model computes the tissue deformation this node describes, for reconstructed real-world impacts.
Divergences from the human mechanism
calibration provenance qualifying
Tissue material properties and the reconstructed head loading are taken from published data and reconstruction rather than measured in the injured individuals whose imaging it is compared with, so agreement is at the level of spatial pattern, not individual prediction.
Show evidence (1 reference)
PMID:28043957 SUPPORT Computational
"Our results show that brain tissue deformation induced by head impact loading is greatest in sulcal locations, where pathology in cases of chronic traumatic encephalopathy is observed."
The model reproduces the spatial pattern of tissue deformation and relates it to where pathology is found.
Diffuse Axonal Injury partially recapitulates fidelity: moderate observes: tissue High-strain regions predicted by the model coincide with white matter abnormality on patient imaging and, in the rat version, with axonal and glial injury on histology.
Limitations: The model outputs strain and strain rate, not axonal damage; agreement with axonal injury is a spatial correlation, and the histological validation was done in rats.
Divergences from the human mechanism
proxy quantity qualifying
The model's quantity is tissue strain and strain rate; the node's quantity is damage to axons. Strain stands in for axonal injury through an injury threshold rather than being the injury itself.
species mismatch qualifying
The validation against histology, the step that ties strain to axonal and glial damage, used a rat model of controlled cortical impact; the human evidence is diffusion imaging, which is an indirect measure of axonal injury.
Show evidence (2 references)
PMID:28043957 SUPPORT Human Clinical
"Diffusion tensor imaging showed converging imaging abnormalities within sulcal regions with a significant decrease in fractional anisotropy in the patient group compared to controls within the sulci."
Patient imaging agrees with the regions of high predicted strain.
+ 1 more reference
Show evidence (1 reference)
PMID:28043957 SUPPORT Computational
"A high fidelity 3D computational model of brain injury biomechanics was developed and the contours of strain and strain rate at the grey matter-white matter boundary were mapped."
Describes the model.
{ }

Source YAML

click to show 
name: Traumatic Brain Injury
creation_date: "2026-10-01T04:00:00Z"
category: Complex
description: >-
  Damage to the brain caused by an external mechanical force: a blow to the head,
  rapid acceleration and deceleration, penetration, or blast. The injury unfolds
  in two stages. The primary injury is mechanical and happens in milliseconds:
  tissue is deformed, vessels tear, and axons are stretched beyond their tolerance.
  A secondary injury cascade then develops over hours to days, driven by
  excitotoxic glutamate release, spreading depolarisations, blood-brain barrier
  disruption, cytotoxic brain swelling and raised intracranial pressure, and
  systemic insults such as hypotension and hypoxia. In a proportion of survivors
  a chronic phase follows, with neuroinflammation and white matter degeneration
  that persist for years and an increased risk of dementia. Severity ranges from
  concussion to coma, and it is graded clinically by the Glasgow Coma Scale and
  the duration of loss of consciousness and post-traumatic amnesia rather than
  by mechanism.
synonyms:
- TBI
- head injury
disease_term:
  preferred_term: traumatic brain injury
  term:
    id: MONDO:0858950
    label: traumatic brain injury
notes: >-
  Modelling scope. This entry follows the injury granularity rule in design
  decision 3f: traumatic brain injury is curated as an entry in its own right
  because the tissue response to the injury, not only its late sequelae, is the
  clinical entity that is managed and studied. Severity (mild, moderate, severe)
  is a gradient of one exposure and is described in the environmental record and
  the progression phases, not split into subtypes. Focal contusion and diffuse
  axonal injury usually co-occur in the same patient, so they are modelled as
  parallel branches from the mechanical injury node rather than as subtypes.
  Shared cascades are not re-derived here: the axonal branch conforms to
  focal_axonal_injury_wallerian_degeneration, barrier disruption to
  blood_brain_barrier_breakdown, glutamate release and secondary neuronal loss to
  glutamate_excitotoxicity, and chronic glial activation to
  neuroinflammation_glial_activation. Two downstream disorders are curated
  separately because each runs on its own mechanism once triggered:
  Post-Traumatic_Epilepsy and Chronic_Traumatic_Encephalopathy.


  Brain swelling. The cited human diffusion MRI studies find the swelling that
  raises intracranial pressure after severe injury to be predominantly cellular
  (cytotoxic) rather than vasogenic, so the swelling node is not drawn as a
  consequence of barrier disruption, even though barrier disruption is
  documented in the same patients.


  Persistent symptoms not yet curated. Depression, anxiety, irritability,
  sleep disturbance, dizziness and fatigue are common after injury, including
  mild injury, but are not yet entered as phenotypes because no source cited
  here gives their frequencies or a mechanism linking them to the nodes above.
  APOE e4 has been studied as a modifier of outcome after injury, with
  inconsistent replication, and is likewise not entered as a genetic record.


  Exposure binding. The mechanical injury is left without an exposure_term. ECTO
  has no term for mechanical or traumatic injury: searches of the local ECTO
  build for l~injur, l~trauma, l~concuss, l~impact, l~crush, l~collision,
  l~acceleration and l~force returned no exposure class. XCO:0000968
  (experimental traumatic brain injury) exists but names an experimental
  procedure in animals, not a human exposure.
pathophysiology:
- name: Rapid Head Acceleration and Brain Tissue Deformation
  biological_scale: TISSUE
  description: >-
    The primary, mechanical injury. Impact or inertial loading of the head
    deforms brain tissue within milliseconds. Axons, which are viscoelastic and
    tolerate slow stretch, fail under rapid deformation, and strain concentrates
    at predictable sites such as the depths of cortical sulci and the
    grey-white matter boundary. Where the load tears vessels or bruises cortex
    the result is a focal lesion; where it shears white matter tracts the result
    is diffuse axonal injury.
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:16222127
    reference_title: Diffuse axonal injury in head trauma.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Although axons are supple under normal conditions, they become brittle
      when exposed to rapid deformations associated with brain trauma.
    explanation: >-
      States the biomechanical basis of the primary injury: axonal tolerance
      depends on loading rate, which is why rapid head acceleration injures
      axons.
  - reference: PMID:28043957
    reference_title: Computational modelling of traumatic brain injury predicts
      the location of chronic traumatic encephalopathy pathology.
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      The computational models predicted large strain most prominent at the
      depths of sulci.
    explanation: >-
      A finite-element head model shows that tissue deformation is not uniform
      but concentrates at the depths of sulci.
  downstream:
  - target: Focal Contusion and Intracranial Haemorrhage
    causal_link_type: DIRECT
    description: >-
      Where the load bruises cortex or tears bridging and parenchymal vessels,
      the primary injury produces contusions and intracranial haematomas.
    evidence:
    - reference: PMID:9414327
      reference_title: A population-based study of seizures after traumatic brain
        injuries.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        severe (loss of consciousness or amnesia for more than 24 hours, subdural
        hematoma, or brain contusion)
      explanation: >-
        Subdural haematoma and contusion are the focal lesions of head trauma
        that define severe injury in this population-based cohort.
    - reference: PMID:16174940
      reference_title: 'The contrecoup-coup phenomenon: a new understanding of
        the mechanism of closed head injury.'
      supports: SUPPORT
      evidence_source: OTHER
      directness: INDIRECT
      snippet: >-
        During the process of closed head injury, the brain parenchyma is
        initially displaced away from the site of skull impact and toward the
        contrecoup site resulting in the more severe brain contusion.
      explanation: >-
        Gives the mechanical route from impact to contusion: the brain is
        displaced within the skull and bruised against it. Indirect because the
        conclusion comes from a physical model with fluids of brain and CSF
        density, not from patients.
  - target: Diffuse Axonal Injury
    causal_link_type: DIRECT
    description: >-
      Shear and stretch of white matter tracts during rapid acceleration damages
      the axonal cytoskeleton.
    evidence:
    - reference: PMID:16222127
      reference_title: Diffuse axonal injury in head trauma.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        rapid stretch of axons can damage the axonal cytoskeleton resulting in a
        loss of elasticity and impairment of axoplasmic transport
      explanation: >-
        Links rapid tissue deformation directly to cytoskeletal axonal damage.
    - reference: PMID:33454735
      reference_title: 'From biomechanics to pathology: predicting axonal injury
        from patterns of strain after traumatic brain injury.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Linear mixed effects regression analyses showed that mechanical strain
        and strain rate were significant predictors of in vivo MRI and histology
        changes.
      explanation: >-
        In a rat controlled cortical impact model, the strain computed by a
        finite-element model predicted where white matter and glial injury
        developed, tying the mechanical event to the axonal lesion.
  - target: Blood-Brain Barrier Disruption
    causal_link_type: DIRECT
    description: >-
      The injury disrupts the blood-brain barrier, documented in human brain
      tissue from the acute phase onward.
    evidence:
    - reference: PMID:26574669
      reference_title: Blood-Brain Barrier Disruption Is an Early Event That May
        Persist for Many Years After Traumatic Brain Injury in Humans.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        These preliminary data demonstrate evidence of widespread BBB disruption
        in a proportion of TBI patients emerging in the acute phase
      explanation: >-
        Autopsy evidence that barrier disruption follows a single moderate or
        severe injury in humans.
- name: Focal Contusion and Intracranial Haemorrhage
  biological_scale: TISSUE
  description: >-
    Cortical contusions and extra-axial (subdural, epidural) or intraparenchymal
    haematomas. Bleeding can continue and expand for hours after the impact,
    which is the basis for early antifibrinolytic treatment, and an expanding
    mass raises intracranial pressure and can cause herniation.
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  evidence:
  - reference: PMID:31623894
    reference_title: 'Effects of tranexamic acid on death, disability, vascular
      occlusive events and other morbidities in patients with acute traumatic
      brain injury (CRASH-3): a randomised, placebo-controlled trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Intracranial bleeding is common after traumatic brain injury (TBI) and can
      cause brain herniation and death.
    explanation: >-
      Establishes intracranial bleeding as a common and lethal component of the
      injury.
  downstream:
  - target: Cerebral Contusion
    causal_link_type: DIRECT
    description: The cortical bruise is the clinical and imaging form of this node.
    evidence:
    - reference: PMID:9414327
      reference_title: A population-based study of seizures after traumatic brain
        injuries.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        severe (loss of consciousness or amnesia for more than 24 hours, subdural
        hematoma, or brain contusion)
      explanation: >-
        Names brain contusion as a lesion of head injury, the clinical form this node
        takes.
  - target: Subdural Hemorrhage
    causal_link_type: DIRECT
    description: >-
      Tearing of bridging veins produces the subdural haematoma, one of the
      haemorrhages this node covers.
    evidence:
    - reference: PMID:9414327
      reference_title: A population-based study of seizures after traumatic brain
        injuries.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        severe (loss of consciousness or amnesia for more than 24 hours, subdural
        hematoma, or brain contusion)
      explanation: >-
        Names subdural haematoma as a lesion of head injury, the clinical form this node
        takes.
  - target: Intracranial Hemorrhage
    causal_link_type: DIRECT
    description: Intracranial bleeding is the clinical form of this node.
    evidence:
    - reference: PMID:31623894
      reference_title: 'Effects of tranexamic acid on death, disability, vascular
        occlusive events and other morbidities in patients with acute traumatic
        brain injury (CRASH-3): a randomised, placebo-controlled trial.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Intracranial bleeding is common after traumatic brain injury (TBI)
      explanation: Intracranial bleeding is the clinical form this node takes.
  - target: Excitotoxic Glutamate Release
    causal_link_type: DIRECT
    description: >-
      Extracellular glutamate rises most in patients with focal contusions and
      secondary ischaemia.
    evidence:
    - reference: PMID:9761042
      reference_title: Factors affecting excitatory amino acid release following
        severe human head injury.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Secondary ischemic brain injury and focal contusions were most strongly
        associated with high EAA levels
      explanation: >-
        Cerebral microdialysis in severely injured patients links focal
        contusion to high extracellular excitatory amino acid levels.
  - target: Spreading Depolarisations
    causal_link_type: DIRECT
    description: >-
      Spreading depolarisations arise in injured grey matter, typically around
      contusions in patients who need surgery.
    evidence:
    - reference: PMID:22056157
      reference_title: 'Spreading depolarisations and outcome after traumatic
        brain injury: a prospective observational study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Pathological waves of spreading mass neuronal depolarisation arise
        repeatedly in injured, but potentially salvageable, grey matter in
        50-60% of patients after traumatic brain injury (TBI).
      explanation: >-
        Places spreading depolarisations in injured grey matter after TBI.
  - target: Cytotoxic Brain Swelling and Raised Intracranial Pressure
    causal_link_type: DIRECT
    description: >-
      Expanding haematoma adds intracranial volume and can cause herniation.
    evidence:
    - reference: PMID:31623894
      reference_title: 'Effects of tranexamic acid on death, disability, vascular
        occlusive events and other morbidities in patients with acute traumatic
        brain injury (CRASH-3): a randomised, placebo-controlled trial.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Intracranial bleeding is common after traumatic brain injury (TBI) and
        can cause brain herniation and death.
      explanation: >-
        Herniation is the end point of uncontrolled intracranial mass effect.
- name: Diffuse Axonal Injury
  conforms_to: "focal_axonal_injury_wallerian_degeneration#Focal Axonal Injury"
  biological_scale: CELLULAR
  description: >-
    Multifocal injury to axons in the cerebral white matter, corpus callosum and
    brainstem caused by inertial shear. Damaged axons lose transport, swell into
    varicosities and bulbs that accumulate transported proteins, and may later
    disconnect; current understanding treats most disconnection as a delayed,
    biochemically driven secondary axotomy rather than immediate tearing. It is a
    principal determinant of loss of consciousness and of long-term outcome, and
    it is hard to see on conventional imaging. In this entry the node is the
    trauma-specific instance of the module's focal axonal injury trigger.
  locations:
  - preferred_term: cerebral white matter
    term:
      id: UBERON:0002437
      label: cerebral hemisphere white matter
  - preferred_term: corpus callosum
    term:
      id: UBERON:0002336
      label: corpus callosum
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: response to axon injury
    term:
      id: GO:0048678
      label: response to axon injury
  evidence:
  - reference: PMID:2767623
    reference_title: 'Diffuse axonal injury in head injury: definition, diagnosis
      and grading.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diffuse axonal injury was identified in 122 of a series of 434 fatal
      non-missile head injuries
    explanation: >-
      Neuropathological series establishing diffuse axonal injury as common in
      fatal closed head injury.
  - reference: PMID:16222127
    reference_title: Diffuse axonal injury in head trauma.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Subsequent swelling of the axon occurs in discrete bulb formations or in
      elongated varicosities that accumulate transported proteins.
    explanation: >-
      Describes the transport failure and axonal swelling that follow the
      mechanical insult.
  - reference: PMID:33006648
    reference_title: 'Traumatic axonal injury (TAI): definitions, pathophysiology
      and imaging-a narrative review.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      This theory has now been partially abandoned in favor of a more refined
      theory involving biochemical processes such as protein cleavage and DNA
      breakdown, ultimately leading to an inflammation cascade and cell
      apoptosis, a process now described as secondary axotomy.
    explanation: >-
      Supports treating axonal disconnection as a delayed biochemical process
      rather than immediate mechanical tearing, which is what the module models.
  downstream:
  - target: White Matter Degeneration and Circuit Disconnection
    causal_link_type: DIRECT
    description: >-
      Swollen axons disconnect and degenerate, and white matter is lost over the
      following months and years.
    evidence:
    - reference: PMID:16222127
      reference_title: Diffuse axonal injury in head trauma.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Ultimately, swollen axons may become disconnected and contribute to
        additional neuropathologic changes in brain tissue.
      explanation: >-
        Links axonal swelling to disconnection and wider tissue damage.
  - target: Loss of Consciousness
    causal_link_type: DIRECT
    description: >-
      Diffuse axonal injury is thought to account for much of the clinical
      deficit after closed head injury, including loss of consciousness; it was
      historically defined clinically by prolonged unconsciousness without a mass
      lesion.
    evidence:
    - reference: PMID:16222127
      reference_title: Diffuse axonal injury in head trauma.
      supports: SUPPORT
      evidence_source: OTHER
      directness: INDIRECT
      snippet: >-
        DAI may largely account for the clinical manifestations of brain trauma.
      explanation: >-
        A review-level statement attributing the clinical deficit, including
        disturbed consciousness, largely to diffuse axonal injury.
  - target: Coma
    causal_link_type: DIRECT
    description: >-
      Widespread axonal injury disconnects the networks that sustain arousal,
      and prolonged unconsciousness without a mass lesion was the original
      clinical definition of diffuse axonal injury.
    evidence:
    - reference: PMID:33006648
      reference_title: 'Traumatic axonal injury (TAI): definitions,
        pathophysiology and imaging-a narrative review.'
      supports: SUPPORT
      evidence_source: OTHER
      directness: INDIRECT
      snippet: >-
        In the past, DAI (diffuse axonal injury) was defined as prolonged (> 6 h)
        loss of consciousness (LOC), without a visible mass lesion.
      explanation: >-
        The historical clinical definition ties diffuse axonal injury to
        prolonged unconsciousness in the absence of a focal mass; indirect
        because a definition is not a demonstration of mechanism.
- name: Blood-Brain Barrier Disruption
  conforms_to: "blood_brain_barrier_breakdown#Blood-Brain Barrier Permeability Increase"
  biological_scale: TISSUE
  description: >-
    Leakage of plasma proteins such as fibrinogen and immunoglobulin G into the
    brain parenchyma, seen in a proportion of patients from the acute phase and,
    strikingly, in a similar proportion of survivors examined years after a
    single injury. Whether this persistent leakage drives late
    neurodegeneration is open.
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  evidence:
  - reference: PMID:26574669
    reference_title: Blood-Brain Barrier Disruption Is an Early Event That May
      Persist for Many Years After Traumatic Brain Injury in Humans.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      After TBI, 40% of patients dying in the acute phase and 47% of those
      surviving a year or more from injury showed multifocal, abnormal,
      perivascular, and parenchymal fibrinogen and immunoglobulin G
      immunostaining localized to the gray matter
    explanation: >-
      Quantifies barrier disruption in the acute phase and its persistence in
      long-term survivors.
- name: Excitotoxic Glutamate Release
  conforms_to: "glutamate_excitotoxicity#Excessive Glutamatergic Stimulation and Impaired Glutamate Clearance"
  biological_scale: TISSUE
  description: >-
    Extracellular glutamate and other excitatory amino acids rise to many times
    normal in a subset of severely injured patients, most in those with
    contusions or secondary ischaemia, and high levels track raised intracranial
    pressure and poor outcome. The release correlates with structural amino
    acids, which suggests it reflects membrane damage as much as vesicular
    release.
  biological_processes:
  - preferred_term: glutamate secretion
    term:
      id: GO:0014047
      label: glutamate secretion
  evidence:
  - reference: PMID:9761042
    reference_title: Factors affecting excitatory amino acid release following
      severe human head injury.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The levels of EAAs were increased up to 50 times normal in 30% of the
      patients
    explanation: >-
      Direct microdialysis measurement of excitatory amino acid release in
      severely head-injured patients.
  downstream:
  - target: Secondary Neuronal Loss
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Glutamate excess drives calcium overload and excitotoxic neuronal death,
      the cascade modelled in glutamate_excitotoxicity.
    evidence:
    - reference: PMID:9761042
      reference_title: Factors affecting excitatory amino acid release following
        severe human head injury.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        The magnitude of EAA release in patients with focal contusions and
        ischemic events may be sufficient to exacerbate neuronal damage
      explanation: >-
        The authors infer, from measured concentrations, that release is large
        enough to add neuronal damage; the neuronal death itself was not
        measured.
- name: Spreading Depolarisations
  biological_scale: TISSUE
  description: >-
    Waves of near-complete neuronal and glial depolarisation that propagate
    slowly through injured cortex, recorded by electrocorticography in about
    half of patients undergoing surgery for TBI. Their occurrence, especially in
    electrically silent cortex, independently predicts unfavourable outcome.
    No GO term describes a spreading depolarisation, so the node carries no
    process binding.
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  evidence:
  - reference: PMID:22056157
    reference_title: 'Spreading depolarisations and outcome after traumatic brain
      injury: a prospective observational study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Spreading depolarisations were associated with unfavourable outcome, after
      controlling for conventional prognostic variables.
    explanation: >-
      Independent association of spreading depolarisations with poor outcome in
      a prospective multicentre cohort.
  downstream:
  - target: Secondary Neuronal Loss
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Repeated depolarisations in metabolically compromised cortex are thought to
      extend the lesion. The cited study shows association with outcome, not
      neuronal death directly.
    evidence:
    - reference: PMID:22056157
      reference_title: 'Spreading depolarisations and outcome after traumatic
        brain injury: a prospective observational study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        The possibility that spreading depolarisations have adverse effects on
        the traumatically injured brain, and therefore might be a target in the
        treatment of TBI, deserves further research.
      explanation: >-
        The authors frame a harmful effect on injured tissue as a hypothesis
        consistent with, but not proven by, their outcome association.
- name: Secondary Systemic Insults (Hypotension and Hypoxia)
  biological_scale: ORGANISM
  description: >-
    Arterial hypotension and hypoxaemia occurring between injury and the end of
    resuscitation. They are common, independently associated with worse
    mortality and morbidity, and the main preventable contributors to
    secondary ischaemic brain damage.
  evidence:
  - reference: PMID:8459458
    reference_title: The role of secondary brain injury in determining outcome
      from severe head injury.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hypotension was profoundly detrimental, occurring in 34.6% of these
      patients and associated with a 150% increase in mortality.
    explanation: >-
      Traumatic Coma Data Bank analysis quantifying the frequency and impact of
      hypotension after severe head injury.
  downstream:
  - target: Secondary Neuronal Loss
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Systemic hypotension and hypoxia reduce oxygen delivery to injured brain
      and add ischaemic damage.
    evidence:
    - reference: PMID:8459458
      reference_title: The role of secondary brain injury in determining outcome
        from severe head injury.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        Hypoxia and hypotension are common and detrimental secondary brain
        insults.
      explanation: >-
        Identifies both as secondary brain insults; the link to neuronal loss is
        inferred from outcome rather than measured in tissue.
- name: Cytotoxic Brain Swelling and Raised Intracranial Pressure
  biological_scale: TISSUE
  description: >-
    Brain swelling after severe injury, measured by diffusion MRI in patients,
    is predominantly cellular rather than vasogenic, and it occurs in tissue
    whose blood flow is above the ischaemic range. Swelling and mass lesions
    together raise intracranial pressure, which when refractory is lethal and is
    the target of tiered medical treatment and decompressive craniectomy.
  locations:
  - preferred_term: brain
    term:
      id: UBERON:0000955
      label: brain
  evidence:
  - reference: PMID:16703876
    reference_title: Predominance of cellular edema in traumatic brain swelling
      in patients with severe head injuries.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The brain swelling observed in patients with TBI appears to be
      predominantly cellular, as signaled by low ADC values in brain tissue with
      high levels of water content.
    explanation: >-
      Diffusion MRI in severely injured patients identifies the swelling as
      cellular rather than vasogenic.
  - reference: PMID:16671417
    reference_title: 'Traumatic brain edema in diffuse and focal injury: cellular
      or vasogenic?'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      it is concluded that the predominant form of edema responsible for brain
      swelling and raised ICP is cellular in nature
    explanation: >-
      Links the cellular edema directly to raised intracranial pressure.
  downstream:
  - target: Increased Intracranial Pressure
    causal_link_type: DIRECT
    description: Brain swelling raises intracranial pressure.
    evidence:
    - reference: PMID:16671417
      reference_title: 'Traumatic brain edema in diffuse and focal injury:
        cellular or vasogenic?'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        it is concluded that the predominant form of edema responsible for brain
        swelling and raised ICP is cellular in nature
      explanation: Swelling is the substrate of the raised pressure.
- name: Secondary Neuronal Loss
  conforms_to: "glutamate_excitotoxicity#Excitotoxic Neuronal Death"
  biological_scale: CELLULAR
  description: >-
    Death of neurons beyond the primary lesion during the hours and days after
    injury, to which excitotoxicity, spreading depolarisations and systemic
    ischaemic insults all contribute. It is the stage that neuroprotective drug
    trials have tried, so far unsuccessfully, to prevent.
  cell_types:
  - preferred_term: neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:9761042
    reference_title: Factors affecting excitatory amino acid release following
      severe human head injury.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: >-
      Sustained high ICP and poor outcome were significantly correlated to high
      levels of EAAs
    explanation: >-
      Secondary injury markers track poor outcome; neuronal death is the
      presumed intermediate and was not measured directly.
  downstream:
  - target: Cognitive impairment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Loss of neurons and circuits underlies persisting cognitive deficits.
    evidence:
    - reference: PMID:35173018
      reference_title: 'Cognitive Outcome 1 Year After Mild Traumatic Brain
        Injury: Results From the TRACK-TBI Study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        At 1 year, 13.5% of participants with mTBI had a poor cognitive outcome
        vs 4.5% of controls (p = 0.003).
      explanation: >-
        Establishes the cognitive consequence; the attribution to neuronal loss
        is an inference, not a measurement in this cohort.
- name: Persistent Neuroinflammation
  conforms_to: "neuroinflammation_glial_activation#Reactive Microglial and Astrocytic Activation"
  biological_scale: TISSUE
  description: >-
    Dense reactive microglia in the white matter that are absent acutely but
    appear by three months and persist for up to 18 years in about a quarter of
    long-term survivors of a single injury. Whether this inflammation is a
    response to ongoing white matter degeneration or a driver of it is
    unresolved.
  cell_types:
  - preferred_term: microglial cell
    term:
      id: CL:0000129
      label: microglial cell
  biological_processes:
  - preferred_term: microglial cell activation
    term:
      id: GO:0001774
      label: microglial cell activation
  - preferred_term: neuroinflammatory response
    term:
      id: GO:0150076
      label: neuroinflammatory response
  locations:
  - preferred_term: corpus callosum
    term:
      id: UBERON:0002336
      label: corpus callosum
  evidence:
  - reference: PMID:23365092
    reference_title: Inflammation and white matter degeneration persist for years
      after a single traumatic brain injury.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      these reactive microglia were present in 28% of cases with survival of >1
      year and up to 18 years post-trauma
    explanation: >-
      Autopsy evidence of microglial activation persisting for years after a
      single injury.
  downstream:
  - target: White Matter Degeneration and Circuit Disconnection
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Persistent inflammation co-localises with ongoing white matter
      degradation. The direction of causation is not established, which this
      entry records as a knowledge gap.
    evidence:
    - reference: PMID:23365092
      reference_title: Inflammation and white matter degeneration persist for
        years after a single traumatic brain injury.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        In cases displaying this inflammatory pathology, evidence of ongoing
        white matter degradation could also be observed.
      explanation: >-
        Co-occurrence in the same cases supports an association, not a causal
        direction.
- name: White Matter Degeneration and Circuit Disconnection
  conforms_to: "focal_axonal_injury_wallerian_degeneration#Disconnection of Neural Circuits"
  biological_scale: TISSUE
  description: >-
    Progressive loss of white matter after the injury, measurable as thinning of
    the corpus callosum in long-term survivors, which disconnects cortical
    networks. It is the structural substrate proposed for persisting cognitive
    deficits and for the increased risk of late neurodegeneration.
  locations:
  - preferred_term: corpus callosum
    term:
      id: UBERON:0002336
      label: corpus callosum
  evidence:
  - reference: PMID:23365092
    reference_title: Inflammation and white matter degeneration persist for years
      after a single traumatic brain injury.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      there was a 25% reduction in the corpus callosum thickness with survival >1
      year post-injury
    explanation: >-
      Quantifies white matter loss in long-term survivors.
  downstream:
  - target: Cognitive impairment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Disconnection of white matter networks is the proposed substrate of
      persisting cognitive deficits.
    evidence:
    - reference: PMID:35173018
      reference_title: 'Cognitive Outcome 1 Year After Mild Traumatic Brain
        Injury: Results From the TRACK-TBI Study.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        At 1 year, 13.5% of participants with mTBI had a poor cognitive outcome
        vs 4.5% of controls (p = 0.003).
      explanation: >-
        Establishes the cognitive consequence of injury; its attribution to
        white matter disconnection is inferred.
  - target: Dementia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Long-term white matter degeneration and inflammation are proposed links
      between a single injury and later dementia.
    evidence:
    - reference: PMID:23365092
      reference_title: Inflammation and white matter degeneration persist for
        years after a single traumatic brain injury.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        A single traumatic brain injury is associated with an increased risk of
        dementia
      explanation: >-
        The study's premise ties single injury to dementia risk and examines
        white matter degeneration as a candidate mechanism.
phenotypes:
- name: Loss of Consciousness
  category: Neurologic
  description: >-
    Transient or prolonged loss of consciousness at the time of injury. Its
    duration, together with that of post-traumatic amnesia, is a standard grade
    of severity.
  phenotype_term:
    preferred_term: Loss of consciousness
    term:
      id: HP:0007185
      label: Loss of consciousness
    temporality: ACUTE
  evidence:
  - reference: PMID:9414327
    reference_title: A population-based study of seizures after traumatic brain
      injuries.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Injuries were classified as mild (loss of consciousness or amnesia lasting
      less than 30 minutes), moderate (loss of consciousness for 30 minutes to
      24 hours or a skull fracture)
    explanation: >-
      Loss of consciousness is the feature by which injury severity is graded.
- name: Coma
  category: Neurologic
  description: >-
    Severe traumatic brain injury is conventionally defined by a Glasgow Coma
    Scale score of 8 or less, that is, by coma.
  phenotype_term:
    preferred_term: Coma
    term:
      id: HP:0001259
      label: Coma
    temporality: ACUTE
  evidence:
  - reference: PMID:25493978
    reference_title: A clinical trial of progesterone for severe traumatic brain
      injury.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      with severe TBI (Glasgow Coma Scale score, ≤8
    explanation: >-
      Uses the coma-range Glasgow Coma Scale score as the definition of severe
      injury.
- name: Post-Traumatic Amnesia
  category: Neurologic
  description: >-
    A period of disorientation and failure to lay down new memories after the
    injury; its duration grades severity alongside loss of consciousness. No HPO
    term names post-traumatic amnesia, so the phenotype is bound to the broader
    memory impairment term.
  phenotype_term:
    preferred_term: Post-traumatic amnesia
    term:
      id: HP:0002354
      label: Memory impairment
    temporality: ACUTE
  evidence:
  - reference: PMID:9414327
    reference_title: A population-based study of seizures after traumatic brain
      injuries.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Injuries were classified as mild (loss of consciousness or amnesia lasting
      less than 30 minutes)
    explanation: >-
      Amnesia duration is one of the two clinical features used to grade
      severity.
- name: Cerebral Contusion
  category: Neurologic
  phenotype_term:
    preferred_term: Cerebral contusion
    term:
      id: HP:6000141
      label: Cerebral contusion
  evidence:
  - reference: PMID:9414327
    reference_title: A population-based study of seizures after traumatic brain
      injuries.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      severe (loss of consciousness or amnesia for more than 24 hours, subdural
      hematoma, or brain contusion)
    explanation: Brain contusion is a defining lesion of severe injury.
- name: Subdural Hemorrhage
  category: Neurologic
  phenotype_term:
    preferred_term: Subdural hematoma
    term:
      id: HP:0100309
      label: Subdural hemorrhage
  evidence:
  - reference: PMID:9414327
    reference_title: A population-based study of seizures after traumatic brain
      injuries.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      severe (loss of consciousness or amnesia for more than 24 hours, subdural
      hematoma, or brain contusion)
    explanation: Subdural haematoma is a defining lesion of severe injury.
- name: Intracranial Hemorrhage
  category: Neurologic
  phenotype_term:
    preferred_term: Intracranial hemorrhage
    term:
      id: HP:0002170
      label: Intracranial hemorrhage
    temporality: ACUTE
  evidence:
  - reference: PMID:31623894
    reference_title: 'Effects of tranexamic acid on death, disability, vascular
      occlusive events and other morbidities in patients with acute traumatic
      brain injury (CRASH-3): a randomised, placebo-controlled trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Intracranial bleeding is common after traumatic brain injury (TBI)
    explanation: Intracranial bleeding is a common feature of the injury.
- name: Increased Intracranial Pressure
  category: Neurologic
  description: >-
    Raised intracranial pressure after severe injury, refractory to first-tier
    measures in a subset of patients.
  phenotype_term:
    preferred_term: Increased intracranial pressure
    term:
      id: HP:0002516
      label: Increased intracranial pressure
    temporality: ACUTE
  evidence:
  - reference: PMID:27602507
    reference_title: Trial of Decompressive Craniectomy for Traumatic
      Intracranial Hypertension.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      with traumatic brain injury and refractory elevated intracranial pressure
      (>25 mm Hg)
    explanation: >-
      Refractory intracranial hypertension after TBI is common enough to define
      the population of a 408-patient trial.
- name: Headache
  category: Neurologic
  description: >-
    The most common persisting symptom, reported by most patients in the first
    year and not related to injury severity.
  phenotype_term:
    preferred_term: Post-traumatic headache
    term:
      id: HP:0002315
      label: Headache
  evidence:
  - reference: PMID:21732765
    reference_title: Natural history of headache after traumatic brain injury.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      71% of participants reported headache during the first year after injury
    explanation: >-
      Prospective cohort quantifying post-traumatic headache.
- name: Cognitive impairment
  category: Neurologic
  description: >-
    Persisting deficits in cognition, present at one year even in a meaningful
    fraction of patients with mild injury.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
    temporality: CHRONIC
  evidence:
  - reference: PMID:35173018
    reference_title: 'Cognitive Outcome 1 Year After Mild Traumatic Brain Injury:
      Results From the TRACK-TBI Study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At 1 year, 13.5% of participants with mTBI had a poor cognitive outcome vs
      4.5% of controls (p = 0.003).
    explanation: >-
      Poor cognitive outcome is three times as common after mild injury as in
      controls.
- name: Early Post-Traumatic Seizures
  category: Neurologic
  description: >-
    Acute symptomatic seizures in the first week after injury. These are
    provoked seizures, distinct from the later epilepsy curated separately as
    Post-Traumatic_Epilepsy.
  phenotype_term:
    preferred_term: Early post-traumatic seizure
    term:
      id: HP:0001250
      label: Seizure
    temporality: ACUTE
  evidence:
  - reference: PMID:2115976
    reference_title: A randomized, double-blind study of phenytoin for the
      prevention of post-traumatic seizures.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Between drug loading and day 7, 3.6 percent of the patients assigned to
      phenytoin had seizures, as compared with 14.2 percent of patients assigned
      to placebo
    explanation: >-
      Early seizures occur in about one in seven untreated patients after
      severe injury.
- name: Dementia
  category: Neurologic
  description: >-
    A long-term increase in the risk of all-cause dementia, highest in the first
    months after injury and rising with the number of injuries.
  phenotype_term:
    preferred_term: Dementia
    term:
      id: HP:0000726
      label: Dementia
  evidence:
  - reference: PMID:29653873
    reference_title: 'Long-term risk of dementia among people with traumatic
      brain injury in Denmark: a population-based observational cohort study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      TBI was associated with an increased risk of dementia both compared with
      people without a history of TBI and with people with non-TBI trauma.
    explanation: >-
      Nationwide cohort of 2.8 million people showing an increased dementia
      risk after TBI, also against a non-head trauma comparison group.
environmental:
- name: Mechanical Head Trauma
  presence: PRESENT
  description: >-
    An external mechanical force to the head: impact, rapid acceleration and
    deceleration, penetration, or blast. Falls predominate in high-income
    countries, particularly in people aged 65 and over, and road traffic
    incidents in low- and middle-income countries. Severity is graded by the
    clinical picture rather than by the force, which is rarely measured.
  notes: >-
    No exposure_term. ECTO has no mechanical or traumatic injury exposure class;
    the searches are listed in the entry-level notes.
  evidence:
  - reference: PMID:36183712
    reference_title: 'Traumatic brain injury: progress and challenges in
      prevention, clinical care, and research.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In HICs, most TBI is caused by falls, particularly in older people (aged
      ≥65 years), who often have comorbidities.
    explanation: Identifies falls as the main cause in high-income countries.
  - reference: PMID:36183712
    reference_title: 'Traumatic brain injury: progress and challenges in
      prevention, clinical care, and research.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      In LMICs, the occurrence of TBI is driven by road traffic incidents
    explanation: >-
      Identifies road traffic incidents as the main cause in low- and
      middle-income countries.
  influences_mechanisms:
  - target: Rapid Head Acceleration and Brain Tissue Deformation
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      The external force is what deforms the brain; it is the initiating event
      of every downstream process in this entry.
    evidence:
    - reference: PMID:33454735
      reference_title: 'From biomechanics to pathology: predicting axonal injury
        from patterns of strain after traumatic brain injury.'
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: BACKGROUND
      snippet: >-
        White matter tracts are damaged by high shear forces during impact,
        resulting in axonal injury
      explanation: >-
        States that the impact force produces the tissue shear that injures
        white matter.
prevalence:
- population: Worldwide
  measure_type: ANNUAL_INCIDENCE
  rate_denominator: POPULATION_PER_YEAR
  notes: >-
    A modelled estimate of 69 million (95% CI 64-74 million) new cases each year
    from all causes. The source gives regional rates but not a single worldwide
    rate per 100,000, so none is asserted here.
  evidence:
  - reference: PMID:29701556
    reference_title: Estimating the global incidence of traumatic brain injury.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sixty-nine million (95% CI 64-74 million) individuals worldwide are
      estimated to sustain a TBI each year.
    explanation: Global annual incidence estimate.
- population: North America (WHO region), modelled estimate
  measure_type: ANNUAL_INCIDENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 1299
  rate_low: 650
  rate_high: 1947
  rate_denominator: POPULATION_PER_YEAR
  notes: >-
    The highest regional incidence in the source, 1299 per 100,000 per year;
    the source notes that regional rates are highest where data quality is
    highest, so the regional ranking partly reflects ascertainment.
  evidence:
  - reference: PMID:29701556
    reference_title: Estimating the global incidence of traumatic brain injury.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The overall incidence of TBI per 100,000 people was greatest in North
      America (1299 cases, 95% CI 650-1947)
    explanation: Regional annual incidence per 100,000.
progression:
- phase: Primary injury
  age_range: Milliseconds to minutes after impact
  notes: >-
    Mechanical deformation of brain tissue, vessel tearing and axonal stretch.
    Nothing done after the event can reverse it; prevention (helmets, fall and
    road safety) is the only intervention at this phase.
  evidence:
  - reference: PMID:16222127
    reference_title: Diffuse axonal injury in head trauma.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      they become brittle when exposed to rapid deformations associated with
      brain trauma
    explanation: The primary injury is the mechanical failure of tissue at impact.
- phase: Secondary injury
  age_range: Hours to days after injury
  notes: >-
    Expanding haemorrhage, excitotoxicity, spreading depolarisations, brain
    swelling with raised intracranial pressure, and systemic hypotension and
    hypoxia. This is the phase that acute care tries to limit.
  evidence:
  - reference: PMID:8459458
    reference_title: The role of secondary brain injury in determining outcome
      from severe head injury.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hypoxia and hypotension are common and detrimental secondary brain
      insults.
    explanation: Characterises the preventable secondary insults of this phase.
- phase: Chronic phase
  age_range: Months to decades after injury
  notes: >-
    Persistent neuroinflammation, white matter degeneration and, in some
    survivors, barrier leakage, with persisting symptoms and an increased risk
    of dementia. The 2022 Lancet Neurology Commission describes TBI as a chronic
    disease as well as an acute condition.
  evidence:
  - reference: PMID:36183712
    reference_title: 'Traumatic brain injury: progress and challenges in
      prevention, clinical care, and research.'
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      TBI is increasingly documented not only as an acute condition but also as
      a chronic disease with long-term consequences, including an increased risk
      of late-onset neurodegeneration.
    explanation: Supports a distinct chronic phase.
  - reference: PMID:23365092
    reference_title: Inflammation and white matter degeneration persist for years
      after a single traumatic brain injury.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These data present striking evidence of persistent inflammation and
      ongoing white matter degeneration for many years after just a single
      traumatic brain injury in humans.
    explanation: Tissue evidence for an active chronic phase.
treatments:
- name: Tranexamic Acid
  description: >-
    Antifibrinolytic given within three hours of injury to limit expansion of
    intracranial bleeding. In the CRASH-3 trial it reduced head injury-related
    death in mild-to-moderate injury but not in severe injury, and earlier
    treatment was more effective.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: tranexamic acid
      term:
        id: CHEBI:48669
        label: tranexamic acid
  target_mechanisms:
  - target: Focal Contusion and Intracranial Haemorrhage
    treatment_effect: INHIBITS
    description: Limits continued intracranial bleeding by inhibiting fibrinolysis.
  evidence:
  - reference: PMID:31623894
    reference_title: 'Effects of tranexamic acid on death, disability, vascular
      occlusive events and other morbidities in patients with acute traumatic
      brain injury (CRASH-3): a randomised, placebo-controlled trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our results show that tranexamic acid is safe in patients with TBI and that
      treatment within 3 h of injury reduces head injury-related death.
    explanation: >-
      Randomised evidence of benefit from early antifibrinolytic treatment.
- name: Decompressive Craniectomy
  description: >-
    Removal of part of the skull to relieve refractory intracranial
    hypertension. It lowers pressure reliably; its effect on outcome depends on
    the setting. As a last-tier treatment for refractory pressure it reduced
    mortality but left more survivors in a vegetative state or severely
    disabled, and used early in diffuse injury it worsened functional outcome.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Decompressive craniectomy
    term:
      id: NCIT:C51791
      label: Craniectomy
  target_mechanisms:
  - target: Cytotoxic Brain Swelling and Raised Intracranial Pressure
    treatment_effect: BYPASSES
    description: >-
      Relieves the pressure by enlarging the intracranial space rather than by
      reducing the swelling itself.
  evidence:
  - reference: PMID:27602507
    reference_title: Trial of Decompressive Craniectomy for Traumatic
      Intracranial Hypertension.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At 6 months, decompressive craniectomy in patients with traumatic brain
      injury and refractory intracranial hypertension resulted in lower
      mortality and higher rates of vegetative state, lower severe disability,
      and upper severe disability than medical care.
    explanation: >-
      Supports a mortality benefit as last-tier treatment, at the cost of more
      severely disabled survivors.
  - reference: PMID:21434843
    reference_title: Decompressive craniectomy in diffuse traumatic brain injury.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      early bifrontotemporoparietal decompressive craniectomy decreased
      intracranial pressure and the length of stay in the ICU but was associated
      with more unfavorable outcomes
    explanation: >-
      Used early in diffuse injury, the operation lowered pressure but worsened
      functional outcome, so it is not a general benefit.
- name: Corticosteroids
  description: >-
    Not recommended. High-dose methylprednisolone was given for decades on the
    rationale of reducing brain swelling and inflammation; in the 10,008-patient
    CRASH trial it increased death within two weeks.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: methylprednisolone
      term:
        id: CHEBI:6888
        label: 6alpha-methylprednisolone
  evidence:
  - reference: PMID:15474134
    reference_title: 'Effect of intravenous corticosteroids on death within 14
      days in 10008 adults with clinically significant head injury (MRC CRASH
      trial): randomised placebo-controlled trial.'
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Compared with placebo, the risk of death from all causes within 2 weeks
      was higher in the group allocated corticosteroids (1052 [21.1%] vs 893
      [17.9%] deaths; relative risk 1.18 [95% CI 1.09-1.27]; p=0.0001).
    explanation: >-
      Refutes benefit: in a 10,008-patient randomised trial, two-week mortality
      was higher on corticosteroids than on placebo.
- name: Early Seizure Prophylaxis
  description: >-
    Phenytoin, or in current practice levetiracetam, given for about a week
    after severe injury. In the pivotal randomised trial it cut seizures in the
    first week from 14.2 to 3.6 percent but did not reduce later seizures, so it
    suppresses early provoked seizures and does not prevent post-traumatic
    epilepsy. The epilepsy is curated separately as Post-Traumatic_Epilepsy.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: phenytoin
      term:
        id: CHEBI:8107
        label: phenytoin
    - preferred_term: levetiracetam
      term:
        id: CHEBI:6437
        label: levetiracetam
  target_phenotypes:
  - preferred_term: Early post-traumatic seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:2115976
    reference_title: A randomized, double-blind study of phenytoin for the
      prevention of post-traumatic seizures.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Phenytoin exerts a beneficial effect by reducing seizures only during the
      first week after severe head injury.
    explanation: >-
      Randomised evidence that prophylaxis reduces early seizures, and only
      early seizures.
  - reference: PMID:2115976
    reference_title: A randomized, double-blind study of phenytoin for the
      prevention of post-traumatic seizures.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Between day 8 and the end of year 1, 21.5 percent of the phenytoin group
      and 15.7 percent of the placebo group had seizures
    explanation: >-
      Refutes any effect on late seizures, which is why prophylaxis is not
      continued to prevent epilepsy.
- name: Hyperosmolar Therapy
  description: >-
    Mannitol or hypertonic saline given to lower raised intracranial pressure,
    in routine use in moderate to severe injury. Randomised evidence has not
    shown that either agent improves functional outcome or survival, or that
    one is better than the other, and continuous prophylactic hypertonic
    saline did not improve six-month neurological outcome.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: mannitol
      term:
        id: CHEBI:29864
        label: mannitol
    - preferred_term: hypertonic saline
      term:
        id: CHEBI:26710
        label: sodium chloride
  target_mechanisms:
  - target: Cytotoxic Brain Swelling and Raised Intracranial Pressure
    treatment_effect: INHIBITS
    description: >-
      Draws water from brain tissue into the circulation to lower intracranial
      pressure.
  evidence:
  - reference: PMID:37380894
    reference_title: 'Hypertonic Saline Versus Other Intracranial-Pressure-Lowering
      Agents for Patients with Acute Traumatic Brain Injury: A Systematic Review
      and Meta-analysis.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: BACKGROUND
    snippet: >-
      Hyperosmolar therapies, such as hypertonic saline (HTS) and mannitol, are
      in routine clinical use for lowering ICP in TBI.
    explanation: >-
      Establishes hyperosmolar therapy as standard treatment for raised
      intracranial pressure in TBI.
  - reference: PMID:37380894
    reference_title: 'Hypertonic Saline Versus Other Intracranial-Pressure-Lowering
      Agents for Patients with Acute Traumatic Brain Injury: A Systematic Review
      and Meta-analysis.'
    supports: REFUTE
    evidence_source: OTHER
    snippet: >-
      We found no evidence of an effect of HTS on clinically important outcomes
      and that HTS is associated with adverse hypernatremia.
    explanation: >-
      Meta-analysis of ten randomised trials finding no outcome benefit of
      hypertonic saline over other pressure-lowering agents.
  - reference: PMID:34032829
    reference_title: 'Effect of Continuous Infusion of Hypertonic Saline vs
      Standard Care on 6-Month Neurological Outcomes in Patients With Traumatic
      Brain Injury: The COBI Randomized Clinical Trial.'
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      treatment with continuous infusion of 20% hypertonic saline compared with
      standard care did not result in a significantly better neurological
      status at 6 months
    explanation: >-
      Prophylactic continuous hypertonic saline did not improve outcome in a
      370-patient randomised trial.
- name: Haematoma Evacuation
  description: >-
    Craniotomy to remove a space-occupying haematoma. Prompt removal of a
    significant subdural or extradural haematoma is established practice. For
    traumatic intraparenchymal haemorrhage the benefit of early surgery is
    uncertain: the only randomised trial, stopped early, found fewer deaths
    with early surgery but a non-significant difference in unfavourable
    outcome.
  therapeutic_modality: SURGERY
  treatment_term:
    preferred_term: Craniotomy for haematoma evacuation
    term:
      id: NCIT:C15214
      label: Craniotomy
  target_mechanisms:
  - target: Focal Contusion and Intracranial Haemorrhage
    treatment_effect: INHIBITS
    description: Removes the haematoma and its mass effect.
  evidence:
  - reference: PMID:25738794
    reference_title: 'Early Surgery versus Initial Conservative Treatment in
      Patients with Traumatic Intracerebral Hemorrhage (STITCH[Trauma]): The
      First Randomized Trial.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: BACKGROUND
    snippet: >-
      Prompt surgical removal of significant subdural (SDH) and extradural
      hemorrhage (EDH) is well established
    explanation: >-
      States that evacuation of significant extra-axial haematomas is
      established practice.
  - reference: PMID:25738794
    reference_title: 'Early Surgery versus Initial Conservative Treatment in
      Patients with Traumatic Intracerebral Hemorrhage (STITCH[Trauma]): The
      First Randomized Trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There were significantly more deaths in the first 6 months in the initial
      conservative treatment group (33% vs. 15%; p=0.006).
    explanation: >-
      Randomised evidence of lower mortality with early surgery for traumatic
      intraparenchymal haemorrhage, from a trial stopped early.
- name: Therapeutic Hypothermia
  description: >-
    Cooling to 32-35 degrees Celsius to lower intracranial pressure. It lowers
    pressure but did not improve outcome, and functional outcome was worse than
    with standard care in the Eurotherm3235 trial.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: Therapeutic hypothermia
    term:
      id: NCIT:C219994
      label: Induction and Maintenance of Total Body Hypothermia
  evidence:
  - reference: PMID:26444221
    reference_title: Hypothermia for Intracranial Hypertension after Traumatic
      Brain Injury.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      therapeutic hypothermia plus standard care to reduce intracranial pressure
      did not result in outcomes better than those with standard care alone
    explanation: Refutes a functional benefit of hypothermia for raised pressure.
- name: Amantadine
  description: >-
    Given during rehabilitation to patients in a vegetative or minimally
    conscious state weeks after injury. In a 184-patient randomised trial it
    accelerated functional recovery during four weeks of treatment, but the
    advantage was not sustained after the drug was stopped. It acts on recovery
    of function rather than on any injury mechanism in this entry, so it carries
    no target_mechanisms link.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: amantadine
      term:
        id: CHEBI:2618
        label: amantadine
  target_phenotypes:
  - preferred_term: Coma
    term:
      id: HP:0001259
      label: Coma
  evidence:
  - reference: PMID:22375973
    reference_title: Placebo-controlled trial of amantadine for severe traumatic
      brain injury.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Amantadine accelerated the pace of functional recovery during active
      treatment in patients with post-traumatic disorders of consciousness.
    explanation: >-
      Randomised evidence that amantadine speeds recovery from prolonged
      post-traumatic disorders of consciousness while it is given.
  - reference: PMID:22375973
    reference_title: Placebo-controlled trial of amantadine for severe traumatic
      brain injury.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The overall improvement in DRS scores between baseline and week 6 (2 weeks
      after treatment was discontinued) was similar in the two groups.
    explanation: >-
      Contradicts a lasting benefit: by two weeks after stopping the drug, the
      two groups had improved by the same amount.
diagnosis:
- name: Head CT
  description: >-
    Non-contrast CT is the first-line test to detect haemorrhage, contusion and
    mass effect needing surgery. It is insensitive to diffuse axonal injury.
  diagnosis_term:
    preferred_term: Computed tomography of the head
    term:
      id: NCIT:C17204
      label: Computed Tomography
  evidence:
  - reference: PMID:30054151
    reference_title: 'Serum GFAP and UCH-L1 for prediction of absence of
      intracranial injuries on head CT (ALERT-TBI): a multicentre observational
      study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Detection of intracranial injuries relies on head CT, which is overused and
      resource intensive.
    explanation: Establishes head CT as the reference test for intracranial injury.
biochemical:
- name: Serum GFAP
  presence: INCREASED
  biomarker_term:
    preferred_term: glial fibrillary acidic protein
    term:
      id: NCIT:C68804
      label: Glial Fibrillary Acidic Protein
  context: >-
    Astroglial protein released into blood after brain injury. Measured within
    12 hours together with UCH-L1, a negative combined result rules out
    CT-visible intracranial injury with high sensitivity in patients with a
    Glasgow Coma Scale score of 9-15. The combined test is used to avoid CT, not
    to diagnose injury.
  evidence:
  - reference: PMID:30054151
    reference_title: 'Serum GFAP and UCH-L1 for prediction of absence of
      intracranial injuries on head CT (ALERT-TBI): a multicentre observational
      study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These results show the high sensitivity and NPV of the UCH-L1 and GFAP
      test.
    explanation: >-
      Validates the two-marker blood test, of which GFAP is one component, for
      ruling out CT-visible injury.
- name: Serum UCH-L1
  presence: INCREASED
  biomarker_term:
    preferred_term: ubiquitin C-terminal hydrolase L1
    term:
      id: NCIT:C105388
      label: Ubiquitin Carboxyl-Terminal Hydrolase Isozyme L1
  context: >-
    Neuronal protein released into blood after brain injury; the second
    component of the combined GFAP and UCH-L1 test used to rule out CT-visible
    injury.
  evidence:
  - reference: PMID:30054151
    reference_title: 'Serum GFAP and UCH-L1 for prediction of absence of
      intracranial injuries on head CT (ALERT-TBI): a multicentre observational
      study.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These results show the high sensitivity and NPV of the UCH-L1 and GFAP
      test.
    explanation: >-
      Validates the two-marker blood test, of which UCH-L1 is one component, for
      ruling out CT-visible injury.
clinical_trials:
- name: NCT00822900
  phase: PHASE_III
  status: TERMINATED
  description: >-
    ProTECT III. Intravenous progesterone within 4 hours of moderate to severe
    injury, stopped for futility. With SyNAPSe it ended the progesterone
    neuroprotection programme despite strong preclinical data.
  evidence:
  - reference: PMID:25493974
    reference_title: Very early administration of progesterone for acute
      traumatic brain injury.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This clinical trial did not show a benefit of progesterone over placebo in
      the improvement of outcomes in patients with acute TBI.
    explanation: Negative phase 3 result for a neuroprotective agent.
- name: NCT01143064
  phase: PHASE_III
  status: COMPLETED
  description: >-
    SyNAPSe. Progesterone for severe injury in 1195 patients; no effect on
    outcome.
  evidence:
  - reference: PMID:25493978
    reference_title: A clinical trial of progesterone for severe traumatic brain
      injury.
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Primary and secondary efficacy analyses showed no clinical benefit of
      progesterone in patients with severe TBI.
    explanation: Negative phase 3 result for a neuroprotective agent.
- name: NCT01068522
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: >-
    BEST-TRIP. Management guided by monitored intracranial pressure was not
    superior to management guided by imaging and clinical examination.
  evidence:
  - reference: PMID:23234472
    reference_title: A trial of intracranial-pressure monitoring in traumatic
      brain injury.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      care focused on maintaining monitored intracranial pressure at 20 mm Hg or
      less was not shown to be superior to care based on imaging and clinical
      examination
    explanation: >-
      Questions whether a pressure threshold is the right treatment target.
computational_models:
- name: Finite-Element Head Model of Brain Injury Biomechanics
  description: >-
    A high-fidelity three-dimensional finite-element model of the human head
    that computes strain and strain rate in brain tissue for a given head
    loading. Applied to a helmet-to-helmet American football impact, a fall and
    a road traffic collision, it predicts that strain concentrates at the depths
    of sulci, and patient diffusion tensor imaging shows abnormalities in the
    same sulcal regions. A rat version of the model was later validated against
    histology after controlled cortical impact.
  model_type: BIOMECHANICAL
  model_format: finite-element mesh
  publication: PMID:28043957
  modeled_mechanisms:
  - target: Rapid Head Acceleration and Brain Tissue Deformation
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: TISSUE
    description: >-
      The model computes the tissue deformation this node describes, for
      reconstructed real-world impacts.
    divergences:
    - divergence_type: CALIBRATION_PROVENANCE
      materiality: QUALIFYING
      description: >-
        Tissue material properties and the reconstructed head loading are taken
        from published data and reconstruction rather than measured in the
        injured individuals whose imaging it is compared with, so agreement is
        at the level of spatial pattern, not individual prediction.
    evidence:
    - reference: PMID:28043957
      reference_title: Computational modelling of traumatic brain injury
        predicts the location of chronic traumatic encephalopathy pathology.
      supports: SUPPORT
      evidence_source: COMPUTATIONAL
      snippet: >-
        Our results show that brain tissue deformation induced by head impact
        loading is greatest in sulcal locations, where pathology in cases of
        chronic traumatic encephalopathy is observed.
      explanation: >-
        The model reproduces the spatial pattern of tissue deformation and
        relates it to where pathology is found.
  - target: Diffuse Axonal Injury
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: TISSUE
    description: >-
      High-strain regions predicted by the model coincide with white matter
      abnormality on patient imaging and, in the rat version, with axonal and
      glial injury on histology.
    limitations: >-
      The model outputs strain and strain rate, not axonal damage; agreement
      with axonal injury is a spatial correlation, and the histological
      validation was done in rats.
    divergences:
    - divergence_type: PROXY_QUANTITY
      materiality: QUALIFYING
      description: >-
        The model's quantity is tissue strain and strain rate; the node's
        quantity is damage to axons. Strain stands in for axonal injury through
        an injury threshold rather than being the injury itself.
    - divergence_type: SPECIES_MISMATCH
      materiality: QUALIFYING
      description: >-
        The validation against histology, the step that ties strain to axonal
        and glial damage, used a rat model of controlled cortical impact; the
        human evidence is diffusion imaging, which is an indirect measure of
        axonal injury.
    evidence:
    - reference: PMID:28043957
      reference_title: Computational modelling of traumatic brain injury
        predicts the location of chronic traumatic encephalopathy pathology.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Diffusion tensor imaging showed converging imaging abnormalities within
        sulcal regions with a significant decrease in fractional anisotropy in
        the patient group compared to controls within the sulci.
      explanation: >-
        Patient imaging agrees with the regions of high predicted strain.
    - reference: PMID:33454735
      reference_title: 'From biomechanics to pathology: predicting axonal injury
        from patterns of strain after traumatic brain injury.'
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Linear mixed effects regression analyses showed that mechanical strain
        and strain rate were significant predictors of in vivo MRI and histology
        changes.
      explanation: >-
        Validates the model's strain prediction against axonal and glial
        histology in rats.
  evidence:
  - reference: PMID:28043957
    reference_title: Computational modelling of traumatic brain injury predicts
      the location of chronic traumatic encephalopathy pathology.
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: >-
      A high fidelity 3D computational model of brain injury biomechanics was
      developed and the contours of strain and strain rate at the grey
      matter-white matter boundary were mapped.
    explanation: Describes the model.
discussions:
- discussion_id: tbi_neuroprotection_translation_failure
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    Why have neuroprotective agents that work robustly in animal models of
    traumatic brain injury, progesterone most prominently, failed in large
    phase 3 trials?
  attaches_to:
  - pathophysiology#Secondary Neuronal Loss
  - clinical_trials#NCT00822900
  - clinical_trials#NCT01143064
  rationale: >-
    The secondary injury cascade was mapped mostly in rodent models, where
    single interventions given at a controlled time after a reproducible injury
    protect tissue. Two independent phase 3 trials of progesterone, and
    earlier trials of other agents, found no benefit in patients. Candidate
    explanations bear directly on the model: human injuries combine focal and
    diffuse lesions in varying proportions, which the rodent injury models do
    not; treatment is given later and less uniformly; and dichotomised
    functional outcome scales may miss real but modest effects. Until one of
    these is shown to account for the failures, the rodent evidence for any
    single node of the secondary cascade should not be read as evidence that
    it is a tractable human target.
  evidence:
  - reference: PMID:25493978
    reference_title: A clinical trial of progesterone for severe traumatic brain
      injury.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These data stand in contrast to the robust preclinical data and results of
      early single-center trials that provided the impetus to initiate phase 3
      trials.
    explanation: >-
      The trial authors state the mismatch between preclinical and phase 3
      results directly.
- discussion_id: tbi_persistent_barrier_disruption_and_neurodegeneration
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Does blood-brain barrier disruption that persists for years after a single
    injury contribute to late neurodegeneration and dementia, or is it a
    marker of damage that has already happened?
  attaches_to:
  - pathophysiology#Blood-Brain Barrier Disruption
  - phenotypes#Dementia
  rationale: >-
    Autopsy evidence shows barrier leakage in nearly half of long-term
    survivors of a single moderate or severe injury, and a single injury
    raises dementia risk. Barrier dysfunction is implicated in other dementias.
    No study links the two in the same patients, so the entry draws no edge
    from barrier disruption to dementia.
  evidence:
  - reference: PMID:26574669
    reference_title: Blood-Brain Barrier Disruption Is an Early Event That May
      Persist for Many Years After Traumatic Brain Injury in Humans.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These preliminary data demonstrate evidence of widespread BBB disruption
      in a proportion of TBI patients emerging in the acute phase and,
      intriguingly, persisting in a high proportion of late survivors.
    explanation: Documents the persistence that motivates the question.
- discussion_id: tbi_inflammation_white_matter_direction
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Is the chronic microglial activation seen years after injury a response to
    ongoing white matter degeneration, or does it drive that degeneration?
  attaches_to:
  - pathophysiology#Persistent Neuroinflammation
  - pathophysiology#White Matter Degeneration and Circuit Disconnection
  rationale: >-
    The two co-occur in the same cases, and the entry draws an indirect edge
    from inflammation to white matter degeneration because that is the
    direction a therapy would exploit. The source study states explicitly that
    the direction is undetermined. If inflammation is a response, targeting it
    would not slow degeneration.
  evidence:
  - reference: PMID:23365092
    reference_title: Inflammation and white matter degeneration persist for years
      after a single traumatic brain injury.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Future studies to determine whether inflammation occurs in response to or,
      conversely, promotes white matter degeneration will be important.
    explanation: The authors state the open question.
📚

References & Deep Research

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Traumatic_Brain_Injury · 2026-10-01T04:20:45Z · View source

First injury entry curated under design decision 3f (injury and trauma granularity). Anchored to MONDO:0858950. The pathograph starts from a mechanical root node (rapid head acceleration and brain tissue deformation) and branches into focal contusion and haemorrhage, diffuse axonal injury, and blood-brain barrier disruption, followed by a secondary cascade (excitotoxic glutamate release, spreading depolarisations, systemic hypotension and hypoxia, cytotoxic swelling with raised intracranial pressure, secondary neuronal loss) and a chronic phase (persistent neuroinflammation, white matter degeneration). Six nodes conform to modules: focal_axonal_injury_wallerian_degeneration (two nodes), blood_brain_barrier_breakdown, glutamate_excitotoxicity (two nodes) and neuroinflammation_glial_activation. Swelling is deliberately not drawn from barrier disruption because the cited human diffusion MRI studies find it predominantly cellular. Severity and lesion type are not subtypes, per decision 3f. Treatments include tranexamic acid and decompressive craniectomy with supporting and refuting trial evidence, corticosteroids and therapeutic hypothermia recorded with refuting evidence, and amantadine for prolonged disorders of consciousness. A finite-element head model is recorded as a BIOMECHANICAL computational model linked to the mechanical root node and, as a PROXY_QUANTITY and SPECIES_MISMATCH divergence, to diffuse axonal injury. Three discussions record the neuroprotection translation failure (HUMAN_MODEL_MISMATCH), whether persistent barrier disruption drives late dementia, and the direction of causation between chronic inflammation and white matter degeneration. The mechanical exposure has no exposure_term; the ECTO searches are recorded in the entry notes. Literature was gathered directly from PubMed, every PMID verified against its fetched abstract (three recalled PMIDs turned out to be unrelated papers and were replaced), and a Falcon deep-research report (research/Traumatic_Brain_Injury-deep-research-falcon.md) was used as a cross-check; it added the amantadine trial. Validation: just validate (schema, terms, references) passes; count-verified-snippets 75/75; 8 of 11 phenotypes are causally connected, with post-traumatic amnesia, headache and early seizures deliberately left unwired because the cited sources do not settle a mechanism for them; check-entity-refs, check-causal-targets and check-duplicate-keys pass; all conforms_to references resolve.

Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 86 citations 2026-10-01T04:11:17.942187

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: Traumatic Brain Injury
  • MONDO ID: MONDO:0858950 (if available)
  • Category: Complex

Research Objectives

Please provide a comprehensive research report on Traumatic Brain Injury covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Present this section as an ordered causal chain first, then the detail below. Open with a numbered sequence of mechanistic steps running from the initiating lesion (mutation, exposure, infection) to the clinical manifestation, one step per line, each naming what it causes next. State the causal verb explicitly ("leads to", "results in") and say where a step is inferred rather than demonstrated. Where the mechanism branches, show the branch. The categories below are a checklist of what to cover within those steps, not the organizing structure — a step may draw on several of them, and a category may contribute to several steps.

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Traumatic brain injury: disease-characteristics report

Scope and evidence convention. Traumatic brain injury (TBI) is an acquired injury caused by external mechanical force, not a Mendelian disease. This report distinguishes population estimates, human clinical studies, expert guidance, animal experiments, cell experiments, and trial registrations. It emphasizes research published in 2023–2024 while retaining older randomized trials when they remain decisive. DOI links and publication dates are supplied where established. PMIDs and exact ontology accession numbers not verified in the retrieved sources are deliberately not invented; proposed ontology labels require database reconciliation before ingestion. (jha2024asinglecellatlas pages 1-3, valente2023clinicalpolicycritical pages 1-2)

A compact set of evidence-graded knowledge-base annotations precedes the detailed report. (huang2024causesandglobal pages 1-2, machamer2022symptomfrequencyand pages 1-3, jha2024asinglecellatlas pages 1-3, legramante2024evaluationofgfapuchl1 pages 1-2, giacino2012placebocontrolledtrialof pages 1-2, hutchinson2016trialofdecompressive pages 1-2)

Domain Validated data or candidate annotation Evidence tier Caveat
Disease model / genetics TBI is externally acquired, not Mendelian. No monogenic etiology, causal pathogenic variant, inheritance pattern, carrier frequency, or clinically indicated TBI genetic test is established. Lipsky et al., 2024; DOI: 10.3389/fnins.2024.1446076. (lipsky2024traumaticbraininjury pages 2-3, lipsky2024traumaticbraininjury pages 3-4) Established disease-level conclusion Do not populate causal-gene or pathogenic-variant fields. APOE, BDNF, COMT, and GRIN2A are possible modifiers or exploratory candidates, not diagnostic genes.
Epidemiology GBD 2019 estimated 27.16 million incident cases, age-standardized incidence of 346 per 100,000, prevalence of 599 per 100,000, and 7.08 million YLDs in 2019. Huang et al., published 18 March 2024; DOI: 10.1016/j.cjtee.2024.03.007. (huang2024causesandglobal pages 1-2) Modeled global population evidence GBD estimates are modeled rather than directly enumerated and depend on source coverage, case definitions, and statistical assumptions.
Persistent phenotype In TRACK-TBI, 53% of participants with TBI reported at least three symptoms at 12 months versus 24% of orthopedic-trauma controls; the prospective analysis included 2,039 participants with TBI. Machamer et al., 2022; DOI: 10.1089/neu.2021.0348. (machamer2022symptomfrequencyand pages 1-3) Prospective multicenter human cohort Participants were treated at level-1 trauma centers and had CT ordered. Symptom endorsement is not TBI-specific and may not generalize to community mTBI.
Single-cell transcriptomics A murine atlas profiled 334,376 cells and identified 23 transcriptionally distinct populations across repetitive closed-head injury, controlled cortical impact, and controlled cortical impact with hemorrhagic shock. Jha et al., 2024; DOI: 10.1016/j.neuron.2024.06.021. (jha2024asinglecellatlas pages 1-3, jha2024asinglecellatlas pages 3-5) High-quality preclinical discovery evidence Mouse models do not reproduce the full heterogeneity of human TBI. Cell states and candidate targets require spatial, functional, and human validation.
Blood biomarkers Among 130 adults with nonpenetrating mTBI and GCS 13–15 tested within 12 hours, CT identified injury in only 7 patients (5%). Combined GFAP/UCH-L1 had sensitivity 1.00 and NPV 1.00; 96 tests were positive and 34 negative. Legramante et al., 2024; DOI: 10.1186/s12245-024-00708-z. (legramante2024evaluationofgfapuchl1 pages 1-2) Single-center retrospective diagnostic study Seven CT-positive cases yielded wide sensitivity uncertainty (95% CI 0.64–1.00). The test supports CT triage but does not independently diagnose or exclude every form of TBI.
Surgery RESCUEicp randomized 408 patients with refractory ICP above 25 mm Hg. Six-month mortality was 26.9% with decompressive craniectomy versus 48.9% with medical care, but surgery increased survival with vegetative state or severe disability; adverse events were 16.3% versus 9.2%. Hutchinson et al., 2016; DOI: 10.1056/NEJMoa1605215. (hutchinson2016trialofdecompressive pages 1-2) Multicenter randomized controlled trial This was rescue treatment for selected refractory intracranial hypertension, not routine care. Survival benefit must be weighed against disability, complications, and patient goals.
Pharmacotherapy / disorders of consciousness In 184 patients in a vegetative or minimally conscious state 4–16 weeks after TBI, amantadine accelerated recovery during four weeks of treatment: Disability Rating Scale slope difference 0.24 points per week versus placebo (P=0.007). Giacino et al., 2012; DOI: 10.1056/NEJMoa1102609. (giacino2012placebocontrolledtrialof pages 1-2) Multicenter double-blind randomized controlled trial Benefit concerned recovery rate during active treatment; overall improvement was similar by week 6 after washout. Results apply to prolonged traumatic disorders of consciousness, not uncomplicated mTBI.
Genetic susceptibility A veteran GWAS included 111,494 TBI cases and 192,991 controls and reported 15 genome-wide significant loci and 14 gene-level signals, including NCAM1, APOE, FTO, and FOXP2. Merritt et al., summarized by Lipsky et al., 2024; DOI: 10.3389/fnins.2024.1446076. (lipsky2024traumaticbraininjury pages 2-3) Large human association study; candidate annotation Signals may reflect exposure propensity or risk-taking rather than biological susceptibility to tissue injury. Significant SNP findings were confined to European-ancestry participants and require diverse replication.

Table: Concise knowledge-base annotations spanning epidemiology, phenotypes, biomarkers, omics, genetics, surgery, and pharmacotherapy. Evidence tiers and caveats distinguish validated clinical findings from modeled estimates and candidate associations.

1. Disease information

TBI comprises an alteration of brain function or evidence of brain pathology after an external force transmitted to the head or body, including impact, acceleration–deceleration, blast, or penetration. It encompasses concussion/mild TBI, focal contusion or hemorrhage, and diffuse axonal injury. A useful initial severity description, not a complete prognostic classification, is Glasgow Coma Scale (GCS) 13–15 for mild, 9–12 for moderate, and 3–8 for severe TBI. The 2025 NIH–NINDS expert initiative proposes supplementing GCS with Clinical, Biomarker, Imaging, and Modifier information; this framework still requires validation and implementation research. (yan2024clinicalmanagementin pages 1-2, manley2025anewcharacterisation pages 1-4)

Identifiers and synonyms. Preserve the supplied identifier MONDO:0858950 as unverified, pending a live MONDO lookup. Relevant coding families are ICD-10 S06.-, intracranial injury and ICD-10-CM injury-specific descendants; selecting an individual code requires documenting hemorrhage type, consciousness status and encounter. Suggested MeSH label: Brain Injuries, Traumatic; independently verify its accession, ICD-11 mapping, and any OMIM or Orphanet cross-reference before database entry. Common names include TBI, traumatic intracranial injury, head injury when brain involvement is established, and concussion for a subset of mild injuries. Head trauma alone does not establish brain injury. No disease-specific OMIM inheritance entry should be assumed. This report synthesizes aggregated studies and guidance, not an individual patient’s electronic health record; one cited comorbidity study derives aggregated estimates from de-identified clinical administrative data. (valente2023clinicalpolicycritical pages 2-4, halabi2024traumaticbraininjury pages 1-2)

2. Etiology, risk and protection

Cause versus modifier. The necessary initiating cause is mechanical energy: falls, road crashes, interpersonal violence, sport, occupational incidents, blasts or penetrating injuries. Falls and road injuries dominate many global settings; the 2024 GBD analysis found higher age-standardized incidence in males, with mechanisms varying across age and geography. An open skull injury can additionally introduce infectious complications, but pathogens do not ordinarily cause TBI. (huang2024causesandglobal pages 1-2, yan2024clinicalmanagementin pages 1-2)

Exposure-related risks include hazardous roads and collision exposure, contact sports, and falls in older adults; anticoagulant treatment principally modifies concern about post-traumatic hemorrhage and clinical assessment rather than constituting a genetic cause. Rural location, socioeconomic disadvantage, prior health, access to trauma care, and other psychosocial factors may modify exposure, care and outcome. In a 2024 Ethiopian trauma-center cohort, road traffic injury and assault were associated with higher odds of head injury than reference mechanisms, but this selected hospital sample cannot supply population-wide risk ratios. The 2023 ACEP policy identifies disproportionate TBI burdens in people experiencing homelessness, incarceration, intimate-partner violence, and rural barriers to care. (huang2024causesandglobal pages 1-2, valente2023clinicalpolicycritical pages 1-2, lipsky2024traumaticbraininjury pages 2-3)

Genetics and gene–environment interaction. There are no established causal TBI genes or genetically protective alleles against experiencing a mechanical injury. A large veteran GWAS, summarized in a 2024 review, analyzed 111,494 TBI cases and 192,991 controls and reported 15 genome-wide-significant loci; gene-based signals included NCAM1, APOE, FTO, and FOXP2. Associations with risk-taking make exposure propensity a plausible contributor; significant findings were predominantly from European-ancestry analyses and do not establish a neuronal injury mechanism. APOE ε4, BDNF rs6265/Val66Met and COMT have been investigated as post-injury outcome modifiers, but replication and effect directions vary. A reported GRIN2A rs11074504–post-traumatic-epilepsy association did not survive multiple-testing correction and must not become a pathogenic-variant annotation. A 2025 pediatric gene-by-injury analysis identified mitochondrial/synaptic hypotheses, but it is a preprint with limited clinical predictive utility. (lipsky2024traumaticbraininjury pages 2-3, lipsky2024traumaticbraininjury pages 3-4, cheng2025interactionsbetweenmild pages 17-20)

Protection. Seat belts, traffic safety, appropriately fitted helmets, reduced collision exposure, fall-risk assessment, and sport-specific rule changes aim to reduce the likelihood or severity of the injury event, not provide biological immunity. The 2023 international concussion consensus supports collision-reducing rules, rugby neuromuscular warm-ups, mouthguards in ice hockey, and removal/clearance protocols to limit repeat injury; effectiveness should not be generalized to every sport or setting. No specific diet, supplement, vaccine, or protective genotype is established as preventing TBI. (patricios2023consensusstatementon pages 1-2, patricios2023consensusstatementon pages 5-6, valente2023clinicalpolicycritical pages 11-13)

3. Phenotypes and quality of life

Phenotypes can begin immediately or after a delay, occur at any age, and range from short-lived to chronic. Frequencies below describe the specified cohort and time point, not universal rates; an unquantified entry should remain frequency unknown in the knowledge base. (machamer2022symptomfrequencyand pages 1-3, valente2023clinicalpolicycritical pages 2-4)

Phenotype and type Typical course, function and suggested HPO label Supported frequency
Headache, dizziness/imbalance, fatigue, light or sound sensitivity; symptoms Acute to persistent; disrupt school, work, mobility and sleep. Suggested HPO labels: Headache, Dizziness, Fatigue, Photophobia, Abnormality of vestibular function. Individual percentages not established by the retrieved abstracts. (machamer2022symptomfrequencyand pages 1-3, lipsky2024traumaticbraininjury pages 1-2)
Confusion, disorientation, amnesia, loss of consciousness; signs/symptoms Acute diagnostic indicators, severity variable. Suggested HPO labels: Confusion, Amnesia, Loss of consciousness. Not quantified across all TBIs. (valente2023clinicalpolicycritical pages 2-4)
Memory/attention deficits and impaired executive function; cognitive manifestations May improve, persist or change years later; affect independence and employment. Suggested labels: Memory impairment, Attention deficit, Executive dysfunction. No defensible pooled phenotype-specific percentage identified. (brett2023longtermmultidomainpatterns pages 1-2, valente2023clinicalpolicycritical pages 2-4)
Irritability, depression, anxiety, sleep disturbance; behavioral/psychiatric symptoms Variable, sometimes persistent; impair relationships and well-being. Suggested labels: Irritability, Depression, Anxiety, Sleep disturbance. Cohort-dependent; not all symptoms are injury-specific. (machamer2022symptomfrequencyand pages 1-3, halabi2024traumaticbraininjury pages 1-2)
Focal weakness, speech impairment, seizures or impaired consciousness; neurologic signs Especially important with focal lesions and severe TBI; seizures may recur later. Suggested labels: Hemiparesis, Aphasia, Seizure, Coma. Frequencies depend strongly on injury subtype; do not propagate a single value. (yan2024clinicalmanagementin pages 1-2, giacino2012placebocontrolledtrialof pages 1-2)
CT hemorrhage/contusion, blood GFAP/UCH-L1 elevation; imaging/laboratory findings, not symptoms Indicate structural injury or support selected CT-triage pathways; neither alone defines every TBI. In one selected 2024 mild-TBI study, 7/130 (5%) had CT-visible injury; not a general population frequency. (legramante2024evaluationofgfapuchl1 pages 1-2)

In TRACK-TBI, 2,039 TBI participants, 257 orthopedic-trauma controls and 300 friend controls were assessed repeatedly: more than half the TBI sample reported at least three symptoms worse than before injury at 12 months; the paper describes 53% versus 24% for TBI versus orthopedic-trauma controls. This is a Level-I-trauma-center, CT-ordered cohort, and symptoms also occurred in controls. Authors’ abstract: “More than 50% of the TBI sample ... continued to endorse three or more symptoms as worse than pre-injury through 12 months post-injury.” Patient-reported outcomes should include Rivermead symptoms, GOSE, EQ-5D, SF-36 and participation measures rather than equating a normal CT with normal quality of life. Study: Machamer et al., March 2022, https://doi.org/10.1089/neu.2021.0348. (machamer2022symptomfrequencyand pages 1-3, brett2023longtermmultidomainpatterns pages 1-2)

4. Genetic and molecular information

Causal genes/variants/chromosomes: not applicable to the initiating injury. Consequently, do not assign ACMG/AMP pathogenicity, germline-versus-somatic causal status, gnomAD carrier frequency, penetrance, copy-number disease lesion, WGS/WES diagnostic yield, or a TBI-specific HGNC causal-gene relationship. Gene annotations should instead be explicitly typed exposure association, response modifier, pathway component, or measured biomarker. Candidate modifiers include APOE (lipid transport/repair), BDNF (activity-dependent trophic signaling; rs6265), and exploratory GRIN2A/GAD2 epilepsy associations; the latter findings are insufficient for clinical prediction. No established genotype-guided TBI pharmacotherapy or protective variant was identified. (lipsky2024traumaticbraininjury pages 2-3, lipsky2024traumaticbraininjury pages 3-4)

Protein and epigenetic signals: astrocytic GFAP and neuron-enriched UCHL1 are injury-associated blood proteins, not mutated causal proteins; axonal APP accumulation can signal interrupted transport, while tau and neurofilament changes are candidate indicators of axonal injury. DNA methylation, histone/RNA modification and microRNAs are research topics, not clinically validated TBI epigenetic tests. A reported human study examined methylation at APP, MAPT and neurofilament genes, but its full primary data were not retrievable here; no locus, effect size or causal conclusion is asserted. (legramante2024evaluationofgfapuchl1 pages 1-2, lipsky2024traumaticbraininjury pages 3-4)

5. Environmental information

Environmental entries should describe exposure to mechanical hazards—traffic, occupational falls, unsafe sporting collisions, blast and interpersonal violence—rather than incorrectly assigning an infectious or toxic etiology. Alcohol intoxication can both contribute to hazardous exposure and confound acute assessment; anticoagulants may alter hemorrhage-management decisions. Infection is chiefly a secondary complication of open injuries or intensive care, not the initiating cause. No zoonotic transmission or vaccination mechanism applies. (yan2024clinicalmanagementin pages 1-2, valente2023clinicalpolicycritical pages 1-2, valente2023clinicalpolicycritical pages 11-13)

6. Mechanism and pathophysiology

Ordered causal chain—“demonstrated” refers to the indicated clinical/imaging or experimental observation; connecting distinct experiments into an individual patient’s full trajectory remains an inference.

  1. Impact, penetration, acceleration–deceleration or blast leads to focal deformation, vascular tearing and/or axonal stretch; these cause contusion, intracranial bleeding or diffuse axonal dysfunction. Demonstrated pathoanatomically and clinically. (yan2024clinicalmanagementin pages 1-2, valente2023clinicalpolicycritical pages 2-4)
  2. Axonal and membrane deformation leads to impaired axonal transport, altered ion flux, glutamate signaling and calcium loading; these result in increased energy demand and synaptic disruption. The exact sequence in an individual human is partly inferred from experimental injury biology. (yan2024clinicalmanagementin pages 1-2, jha2024asinglecellatlas pages 3-5)
  3. Energy–perfusion mismatch and calcium stress lead to mitochondrial impairment, oxidative damage and cell death; in parallel, torn vessels and endothelial injury lead to barrier leakage, hemorrhage and cerebral edema. These interacting branches amplify secondary injury; links to specific bedside symptoms remain partly inferred. (yan2024clinicalmanagementin pages 1-2, lotze2024poloxamer188exerts pages 1-5)
  4. Edema and hematoma lead to raised intracranial pressure (ICP), which reduces cerebral perfusion and results in ischemia or herniation when severe. This link is supported by human physiology and rescue-surgery trials. (hutchinson2016trialofdecompressive pages 1-2, brenner2020understandingtheneuroprotective pages 1-2)
  5. Tissue injury and barrier dysfunction lead to activation of resident microglia and astrocytes plus recruitment of circulating immune cells; their inflammatory signals can result in additional damage or debris clearance and repair. Mouse single-cell data demonstrate cell-state heterogeneity, not one uniformly harmful immune pathway in all patients. (jha2024asinglecellatlas pages 1-3, jha2024asinglecellatlas pages 3-5)
  6. Axonal, cortical and network damage plus variable repair lead to altered consciousness, seizures, focal deficits, cognitive and behavioral symptoms; persistent immune/metabolic changes may contribute to chronic deficits or later neurodegeneration. The last step is an inference at the individual level: observational associations cannot prove that a given late disorder was caused by a particular earlier TBI. (brett2023longtermmultidomainpatterns pages 1-2, halabi2024traumaticbraininjury pages 1-2, jha2024asinglecellatlas pages 1-3)

Upstream versus downstream; cells and pathways. Mechanical disruption is upstream. Glutamatergic excitotoxicity, calcium homeostasis, mitochondrial respiration, reactive oxygen species, neurovascular permeability and cell death bridge the acute insult to downstream edema, ischemia and network failure. Candidate inflammatory circuits include IL1B/TLR and chemokine signaling; RHO-GTPase, MAPK, CREB and lipid/cholesterol pathways were among inferred pathway enrichments in mouse hippocampal proteomics, not clinically established drivers or approved targets. The 2024 Neuron atlas measured 334,376 mouse cells, resolving 23 populations across repetitive closed-head injury, controlled cortical impact (CCI), and CCI plus hemorrhagic shock. Its abstract describes “persistent gene-expression changes in microglia-4 even 6-months after contusional-TBI”; it also identifies an ependymal inflammatory-signaling population. Single-cell expression does not by itself establish intervention efficacy. Jha et al., September 2024, https://doi.org/10.1016/j.neuron.2024.06.021. (jha2024asinglecellatlas pages 1-3, jha2024asinglecellatlas pages 3-5)

Spatial profiling and data visualization. In nine mice, hippocampal laser-microdissection proteomics compared sham, one-day and seven-day injury across CA1/pyramidal layer, stratum moleculare and two dentate-gyrus regions. It found region-specific inflammatory proteins, glucose/lipid-metabolic disturbances and cholesterol-synthesis enrichment. These are mouse molecular signatures, not human diagnostic thresholds. Figure 2’s cropped panels show distinct one- versus seven-day protein changes by hippocampal subregion; the panel supports spatial heterogeneity, not a claim that any depicted protein causes dementia. Maity et al., May 2024, https://doi.org/10.1186/s12014-024-09485-6. (maity2024mappingdynamicmolecular pages 1-2, maity2024mappingdynamicmolecular pages 5-8, maity2024mappingdynamicmolecular media 666596e2)

Suggested ontology mappings, labels only pending accession checks: GO biological processes response to mechanical stimulus, glutamate receptor signaling pathway, calcium ion homeostasis, mitochondrial ATP synthesis, reactive oxygen species metabolic process, inflammatory response, apoptotic process, axon regeneration; GO cellular components axon, synapse, mitochondrion, plasma membrane, nucleus, endoplasmic reticulum, lysosome. Suggested Cell Ontology labels are neuron, astrocyte, microglial cell, oligodendrocyte, brain microvascular endothelial cell, ependymal cell, neutrophil and macrophage. These are candidate annotations, not validated accession-level assertions. (yan2024clinicalmanagementin pages 1-2, jha2024asinglecellatlas pages 3-5, maity2024mappingdynamicmolecular pages 5-8)

7. Anatomical structures

The brain is directly affected: cerebral cortex and subcortical white-matter axons; frontal/temporal regions where impacted; hippocampal circuits relevant to memory; brainstem when struck or compressed; meninges, cerebral vessels and ventricles when hemorrhage, hydrocephalus or raised ICP occur. Injuries may be unilateral, bilateral, focal or diffuse; lateralization must come from the actual imaging report rather than the diagnosis TBI. At tissue scale, neurons, oligodendrocytes/myelin, astrocytes, microglia, vascular endothelium and infiltrating leukocytes may be involved. Secondary systemic effects may involve respiratory, cardiovascular and endocrine systems; associations with incident disorders do not establish identical organ damage in every patient. Suggested UBERON labels: brain, cerebral cortex, corpus callosum, hippocampus, brainstem, cerebral blood vessel, meninx. Suggested GO compartments are listed in §6; accession numbers need verification. (yan2024clinicalmanagementin pages 1-2, halabi2024traumaticbraininjury pages 1-2, maity2024mappingdynamicmolecular pages 5-8, jha2024asinglecellatlas pages 3-5)

8. Temporal development

Onset is acute at any age, including childhood and late life. Initial bleeding and cerebral swelling can worsen over hours; secondary metabolic and inflammatory processes evolve over hours to days. Improvement is common during the first months, but symptom and function trajectories are heterogeneous rather than obligatorily progressive. TRACK-TBI symptom scores declined faster between two weeks and three months—approximately 1.7 points/month—than afterward, approximately 0.2 points/month, in its selected cohort. In TRACK-TBI LONG, outcomes 2–7 years after injury were most often stable, yet 29% of mild and 23% of moderate/severe participants experienced functional decline under the study’s GOSE-based definition; worsening was not universal and occurred in orthopedic controls too. The clinical time windows requiring prompt attention include initial resuscitation/hemorrhage control, evolving intracranial hypertension, and planned rehabilitation/follow-up. There is no cancer-like stage or predictable end-stage sequence for all TBI. (machamer2022symptomfrequencyand pages 1-3, brett2023longtermmultidomainpatterns pages 1-2, brenner2020understandingtheneuroprotective pages 1-2)

9. Inheritance and population epidemiology

The 2024 publication of GBD-2019 estimates reported 27.16 million incident TBIs worldwide in 2019 (95% uncertainty interval [UI] 23.36–31.42 million), age-standardized incidence 346/100,000/year (95% UI 298–401), age-standardized prevalence 599/100,000 (95% UI 573–627), and 7.08 million years lived with disability. A later 2025 publication analyzing GBD-2021 estimated 20.84 million incident TBIs in 2021, with incidence 259/100,000 (95% UI 226–296). Do not interpret the difference between these modeled publications as a measured two-year fall without reconciling their methods, definitions and revisions. Males generally have higher incidence; falls are prominent across age groups, with risk also concentrated in younger crash-exposed and older fall-exposed populations. Regional estimates and apparent sex ratios depend on case ascertainment, injury mechanism and health-care access. Huang et al., online March 2024, https://doi.org/10.1016/j.cjtee.2024.03.007; Yan et al., April 2025, https://doi.org/10.3389/fpubh.2025.1556147. (huang2024causesandglobal pages 1-2, yan2025globalregionaland pages 1-2)

Inheritance, penetrance, expressivity, anticipation, germline mosaicism, founder effects, consanguinity, and carrier frequencies: not applicable to TBI as an acquired mechanical injury. A susceptibility GWAS must not be reclassified as a Mendelian cause; no validated geographic distribution of a TBI-causing variant exists. (jha2024asinglecellatlas pages 1-3, lipsky2024traumaticbraininjury pages 2-3)

10. Diagnostics and differential diagnosis

Clinical assessment. Establish a plausible injury event and a contemporaneous change in consciousness, orientation, memory, neurological function or imaging; document GCS components, pupils, serial neurological examinations, post-traumatic amnesia and competing explanations such as intoxication or medication effects. The 2023 ACEP policy describes mild-TBI indicators including confusion/disorientation, loss of consciousness ≤30 minutes or amnesia <24 hours, with GCS 13–15 after 30 minutes or later presentation; newer ACRM criteria are also referenced by the 2024 TBI literature. A normal CT does not exclude uncomplicated concussion. Exclude primary stroke, spontaneous intracranial hemorrhage, seizure/postictal state, intoxication, hypoglycemia and other non-traumatic causes according to presentation. (valente2023clinicalpolicycritical pages 2-4, lipsky2024traumaticbraininjury pages 2-3)

Imaging and function. Noncontrast head CT is first-line to detect clinically important acute hemorrhage, fracture or mass effect when indicated; the 2023 ACEP policy favors the Canadian CT Head Rule for eligible adults to help avoid unnecessary CT, while cautioning against extrapolating decision-rule exclusions to anticoagulated or otherwise ineligible patients. MRI can characterize selected persistent or diffuse lesions; neither MRI nor PET is a universal diagnostic requirement. For sport concussion, the 2023 Amsterdam statement places SCAT6/Child SCAT6 primarily in the first 72 hours, and SCOAT6/Child SCOAT6 in subacute office assessment. Neurocognitive tests, vestibular/ocular examination, balance assessment and symptom inventories complement rather than replace clinical judgment. EEG is used when seizures or otherwise unexplained impaired consciousness warrant it; biopsy is not routine. (valente2023clinicalpolicycritical pages 1-2, patricios2023consensusstatementon pages 5-6, patricios2023consensusstatementon pages 6-7, yan2024clinicalmanagementin pages 1-2)

Blood and bedside biomarkers. Serum/plasma GFAP and UCH-L1 can help predict CT-visible injury in specified adult mild-TBI pathways, rather than prove or exclude all TBI. In a small 2024 retrospective study of 130 adults sampled within 12 hours, only seven CTs were positive; combined-marker sensitivity was 1.00, with wide 95% CI 0.64–1.00, illustrating why apparent perfect performance must not be generalized. In a separate 2024 polytrauma/shock analysis, an arrival GFAP cut point >286 pg/mL gave AUC 0.77 for CT-diagnosed injury; 3094 pg/mL was an analysis-derived threshold for more severe CT features/progression, not a universal approved cutoff. Legramante et al., October 2024, https://doi.org/10.1186/s12245-024-00708-z; Sperry et al., online May 2024, https://doi.org/10.3171/2024.1.JNS232569. (legramante2024evaluationofgfapuchl1 pages 1-2, sperry2024earlygfapand pages 1-2)

Other tests and screening. Severe injury may require serial CT, invasive ICP monitoring and selected cerebral oxygen or metabolic monitoring; routine electrolytes, blood counts, coagulation studies and glucose evaluate complications and alternative explanations, not a disease-specific metabolic defect. WGS, WES, genetic panels, CMA, karyotyping, FISH, mitochondrial sequencing, repeat-expansion testing, and omics-based diagnostic tests are not standard TBI diagnostics. Genetic work-up is appropriate only for an independently suspected inherited differential diagnosis. There is no asymptomatic newborn/carrier/cascade genetic screening program for TBI; screening instead concerns injury exposure and fall risk. (yan2024clinicalmanagementin pages 1-2, valente2023clinicalpolicycritical pages 11-13, lipsky2024traumaticbraininjury pages 2-3)

11. Outcome and prognosis

TBI outcomes range from complete functional recovery to persistent disability or death. Prognostic descriptors include age, baseline health, initial GCS and pupils, CT abnormalities, hypoxia/hypotension, secondary insults and post-injury function. In the 2023 TRACK-TBI LONG sample of 1,264 including orthopedic controls, functional decline over later follow-up occurred in 29% of mild and 23% of moderate/severe cases; risk of decline after mild TBI rose with age and nonemployment before injury. This observational finding is not a fixed lifetime probability. Brett et al., August 2023, https://doi.org/10.1212/WNL.0000000000207501. (brett2023longtermmultidomainpatterns pages 1-2)

A 2024 US health-system cohort compared 10,200 people with TBI against 10,200 matched unexposed individuals: later recorded comorbidity hazards ranged from HR 1.30 for hypothyroidism to 4.06 for dementia after mild TBI; middle-aged participants had elevated recorded suicidality risk. These are adjusted associations, susceptible to residual confounding and surveillance differences, not proof that every late condition was caused by TBI. Halabi et al., December 2024, https://doi.org/10.1001/jamanetworkopen.2024.50499. A 2024 systematic review found reduced life expectancy after severe TBI, but heterogeneous cohorts preclude assigning one universal five-/ten-year survival rate or lifespan loss to the entire TBI population. https://doi.org/10.23736/S1973-9087.24.08461-2. (halabi2024traumaticbraininjury pages 1-2, brett2023longtermmultidomainpatterns pages 1-2)

12. Treatment and real-world implementation

Algorithm, adapted to severity: stabilize airway, breathing and circulation; prevent hypoxemia and hypotension; assess neurologic status and urgent CT indications; evacuate indicated mass lesions; manage ICP/cerebral perfusion and complications in severe cases; provide individualized symptom treatment, early supported activity when safe and multidisciplinary rehabilitation. The 2024 clinical management review identifies oxygenation, hemodynamics, ICP-directed care, selected hyperosmolar therapy, nutrition and seizure prevention as severe-TBI management components. Suggested NCIT intervention labels—computed tomography, craniotomy, decompressive craniectomy, ventricular drainage, rehabilitation, physical therapy, occupational therapy, speech therapy and drug therapy—need formal NCIT code verification. (yan2024clinicalmanagementin pages 1-2)

  • Acute medication/support: hypertonic saline or mannitol treats selected raised-ICP states; analgesics and rehabilitation-focused symptom management address pain and associated problems; antiseizure medications are used when indicated to prevent early post-traumatic seizures in selected high-risk cases, not as proven prevention of lifelong epilepsy. Tranexamic acid is an antifibrinolytic candidate for appropriately selected, early bleeding-related TBI: a CRASH-3 secondary analysis of patients treated within three hours and excluding moribund cases found 24-hour deaths 2.9% versus 3.9% with placebo (RR 0.74, 95% CI 0.58–0.94), whereas its 28-day all-cause result 14.0% versus 15.1% had a CI crossing no effect. This is a secondary analysis, not proof of benefit for every severity or delayed presentation. Suggested ChEBI labels: tranexamic acid, mannitol, sodium chloride; verify accessions. Brenner et al., 2020, https://doi.org/10.1186/s13054-020-03243-4. (yan2024clinicalmanagementin pages 1-2, brenner2020understandingtheneuroprotective pages 1-2)
  • Neurosurgery: hematoma evacuation and, for selected refractory intracranial hypertension, decompressive craniectomy. In RESCUEicp, randomized patients with ICP >25 mm Hg had six-month mortality 26.9% after surgery versus 48.9% under continued medical care, but survivors more often had vegetative state or severe disability; adverse events were 16.3% versus 9.2%. This is a values-sensitive survival/disability trade-off, not an indication for routine craniectomy in mild TBI. Hutchinson et al., September 2016, https://doi.org/10.1056/NEJMoa1605215. In a 2024 economic evaluation nested in the randomized RESCUE-ASDH trial, craniotomy rather than leaving the bone flap out after subdural-hematoma evacuation had an estimated 0.093 QALY advantage in its UK subset; this economic result does not imply a universal operative choice. https://doi.org/10.1136/bmjopen-2024-085084. (hutchinson2016trialofdecompressive pages 1-2, pyne2024costeffectivenessofcraniotomy pages 1-2)
  • Disorders of consciousness: a double-blind trial of 184 rehabilitating patients in vegetative or minimally conscious states 4–16 weeks after TBI found that amantadine accelerated improvement during four weeks of treatment: Disability Rating Scale slope difference 0.24 points/week, P=0.007. Overall improvement was similar by week six after washout, and serious adverse-event rates did not significantly differ. This result does not justify treating all acute TBI or uncomplicated concussion with amantadine. Giacino et al., March 2012, https://doi.org/10.1056/NEJMoa1102609. (giacino2012placebocontrolledtrialof pages 1-2)
  • Mild TBI and rehabilitation: give return precautions and tailored follow-up; for sport concussion, use 24–48 hours of relative rather than strict rest, then symptom-limited activity and staged school/sport return. Prescribed sub-symptom aerobic exercise can be considered within 2–10 days where assessment and supervision are available. Persistent vestibular, mood, sleep, cognitive, communication and functional problems warrant targeted physical, occupational, speech-language and psychological input. These sports recommendations must not be substituted for severe-injury resuscitation. (patricios2023consensusstatementon pages 1-2, patricios2023consensusstatementon pages 6-7)
  • Experimental versus established: hyperbaric oxygen, stem-cell/extracellular-vesicle approaches, anti-inflammatory biologics, gene editing, ASOs, RNA drugs and precision-genotype therapies are not established disease-modifying TBI treatments. ClinicalTrials.gov lists phase-2 intravenous amantadine safety trial NCT06253923, first posted February 2024, and the phase-2 HOBIT hyperbaric-oxygen optimization trial NCT02407028. Trial registration, recruitment, or an estimated enrollment is not an efficacy result; registry status and dates should be refreshed before implementation. (NCT06253923 chunk 1, NCT02407028 chunk 1)

No reliable universal treatment response rate, genotype-guided algorithm or validated TBI pharmacogenomic recommendation can be assigned across this heterogeneous injury; use the indication-specific effect estimates above. (jha2024asinglecellatlas pages 1-3, lipsky2024traumaticbraininjury pages 2-3)

13. Prevention

Primary: reduce traumatic exposure through road design, seat belts/appropriate helmets, collision-limiting sport rules, occupational protections, violence prevention and fall-risk interventions. The Amsterdam sport consensus additionally recommends removal from play after suspected concussion and medically supervised return; policies and mechanism-specific interventions have stronger support than an unspecified anti-TBI supplement. Secondary: promptly recognize injury, provide appropriately indicated CT and serial reassessment when symptoms evolve, and prevent avoidable hypoxia/hypotension or expanding hemorrhage. Tertiary: mitigate raised ICP and seizures when indicated; offer rehabilitation, follow-up and social support to reduce disability and repeat injury. Fall-risk reassessment is explicitly recommended for suitable emergency-department patients. No vaccine, infectious prophylaxis, newborn genetic screen or carrier counseling prevents mechanically initiated TBI. (patricios2023consensusstatementon pages 1-2, patricios2023consensusstatementon pages 5-6, valente2023clinicalpolicycritical pages 11-13, yan2024clinicalmanagementin pages 1-2)

14. Other species and naturally occurring injury

Natural mechanical brain/head injuries occur in companion animals and wildlife; this is cross-species susceptibility to trauma, not an inherited or transmissible disease. A 2024 naturally injured tawny owl (Strix aluco; NCBI Taxon ID not independently verified) had lethargy, anisocoria, retinal injury, right-hemisphere CT abnormality and abnormal auditory/visual evoked responses. A single case demonstrates feasibility of veterinary neurological, imaging and electrophysiologic assessment, not incidence or breed susceptibility. Veterinary experts describe spontaneously injured dogs and cats as potentially useful complementary translational cohorts, while noting differences in anatomy, treatment context and ascertainment. No breed-specific VBO term, TBI-causal ortholog, animal founder allele or zoonotic route is applicable on this evidence. Vetere et al., August 2024, https://doi.org/10.3389/fvets.2024.1439432; Hall et al., April 2024, https://doi.org/10.1017/cts.2024.513. (vetere2024casereportevaluation pages 1-2, hall2024breakingbarriersin pages 1-2)

15. Model organisms and experimental systems

Mouse (Mus musculus; suggested NCBI Taxon 10090, accession to verify) CCI models a focal cortical contusion; fluid percussion and repetitive closed-head impacts sample different deformation patterns; blast paradigms examine a distinct exposure. Wild-type, genetically modified, aged and sex-comparison cohorts can interrogate immune signaling, axon injury and recovery, but no knockout alone is a model of genetically caused TBI. A mouse blast hippocampus data resource sequenced 17,278 nuclei; the 2024 multi-model mouse atlas found pronounced dependence of cellular states on injury model, region, time and sex. In-vitro brain microvascular endothelial compression/hypoxia systems isolate membrane and barrier processes but omit intact brain circuits, circulation and behavior. Organoids or iPSC systems can be useful research platforms, but clinical phenotype equivalence or a validated TBI diagnostic use was not established in the retrieved evidence. Model resources for follow-up curation include MGI, RGD, ZFIN, GEO and PRIDE; dataset identifiers and alleles must be individually verified. Zhang et al., September 2023, https://doi.org/10.1038/s41597-023-02552-x; Jha et al., September 2024, https://doi.org/10.1016/j.neuron.2024.06.021. (jha2024asinglecellatlas pages 1-3, jha2024asinglecellatlas pages 3-5, lotze2024poloxamer188exerts pages 1-5)

Knowledge-base integrity rule. Record the injury exposure, severity and lesion anatomy, time since injury, population sampled, and evidence type alongside each phenotype or molecular observation. Do not promote injury-associated protein expression, GWAS exposure associations, preclinical pathway enrichment, or a trial-registration intervention to a causal pathogenic variant, universal phenotype frequency or approved targeted therapy. (huang2024causesandglobal pages 1-2, machamer2022symptomfrequencyand pages 1-3, jha2024asinglecellatlas pages 1-3, legramante2024evaluationofgfapuchl1 pages 1-2, lipsky2024traumaticbraininjury pages 2-3, NCT06253923 chunk 1)

References

  1. (jha2024asinglecellatlas pages 1-3): Ruchira M. Jha, Dhivyaa Rajasundaram, Chaim Sneiderman, Brent T. Schlegel, Casey O’Brien, Zujian Xiong, Keri Janesko-Feldman, Ria Trivedi, Vincent Vagni, Benjamin E. Zusman, Joshua S. Catapano, Adam Eberle, Shashvat M. Desai, Ashutosh P. Jadhav, Sandra Mihaljevic, Margaux Miller, Sudhanshu Raikwar, Anupama Rani, Jarrod Rulney, Shima Shahjouie, Itay Raphael, Aditya Kumar, Chia-Ling Phuah, Ethan A. Winkler, Dennis W. Simon, Patrick M. Kochanek, and Gary Kohanbash. A single-cell atlas deconstructs heterogeneity across multiple models in murine traumatic brain injury and identifies novel cell-specific targets. Sep 2024. URL: https://doi.org/10.1016/j.neuron.2024.06.021, doi:10.1016/j.neuron.2024.06.021. This article has 84 citations and is from a highest quality peer-reviewed journal.

  2. (valente2023clinicalpolicycritical pages 1-2): Jonathan H. Valente, John D. Anderson, William F. Paolo, Kelly Sarmiento, Christian A. Tomaszewski, Jason S. Haukoos, Deborah B. Diercks, Deborah B. Diercks, John D. Anderson, Richard Byyny, Christopher R. Carpenter, Benjamin Friedman, Seth R. Gemme, Charles J. Gerardo, Steven A. Godwin, Sigrid A. Hahn, Benjamin W. Hatten, Jason S. Haukoos, Amy Kaji, Heemun Kwok, Bruce M. Lo, Sharon E. Mace, Maggie Moran, Susan B. Promes, Kaushal H. Shah, Richard D. Shih, Scott M. Silvers, Andrea Slivinski, Michael D. Smith, Molly E.W. Thiessen, Christian A. Tomaszewski, Stacy Trent, Jonathan H. Valente, Stephen P. Wall, Lauren M. Westafer, Yanling Yu, Stephen V. Cantrill, John T. Finnell, Travis Schulz, and Kaeli Vandertulip. Clinical policy: critical issues in the management of adult patients presenting to the emergency department with mild traumatic brain injury: approved by acep board of directors, february 1, 2023 clinical policy endorsed by the emergency nurses association (april 5, 2023). Annals of emergency medicine, 81 5:e63-e105, May 2023. URL: https://doi.org/10.1016/j.annemergmed.2023.01.014, doi:10.1016/j.annemergmed.2023.01.014. This article has 12 citations and is from a domain leading peer-reviewed journal.

  3. (huang2024causesandglobal pages 1-2): Xiao-Fei Huang, Shuai-Feng Ma, Xu-Heng Jiang, Ren-Jie Song, Mo Li, Ji Zhang, Tian-Jing Sun, Quan Hu, Wen-Rui Wang, An-Yong Yu, and He Li. Causes and global, regional, and national burdens of traumatic brain injury from 1990 to 2019. Dec 2024. URL: https://doi.org/10.1016/j.cjtee.2024.03.007, doi:10.1016/j.cjtee.2024.03.007. This article has 69 citations.

  4. (machamer2022symptomfrequencyand pages 1-3): Joan Machamer, Nancy Temkin, Sureyya Dikmen, Lindsay D. Nelson, Jason Barber, Phillip Hwang, Kim Boase, Murray B. Stein, Xiaoying Sun, Joseph Giacino, Michael A. McCrea, Sabrina R. Taylor, Sonia Jain, Geoff Manley, Neeraj Badjatia, Yelena Bodien, Ramon Diaz-Arrastia, Ann-Christine Duhaime, V. Ramana Feeser, Adam R. Ferguson, Brandon Foreman, Etienne Gaudette, Shankar Gopinath, Frederick K. Korley, Christopher Madden, Pratik Mukherjee, Laura B. Ngwenya, David Okonkwo, Ava Puccio, Claudia Robertson, Jonathan Rosand, David Schnyer, Mary Vassar, John K. Yue, and Ross Zafonte. Symptom frequency and persistence in the first year after traumatic brain injury: a track-tbi study. Mar 2022. URL: https://doi.org/10.1089/neu.2021.0348, doi:10.1089/neu.2021.0348. This article has 167 citations and is from a domain leading peer-reviewed journal.

  5. (legramante2024evaluationofgfapuchl1 pages 1-2): Jacopo M. Legramante, Marilena Minieri, Marzia Belli, Alfredo Giovannelli, Alessia Agnoli, Daniela Bajo, Lorenza Bellincampi, Anna Maria De Angelis, Alessandro Terrinoni, Massimo Pieri, Eleonora Nicolai, Vito N. Di Lecce, Carla Paganelli, Gianluigi Ferrazza, Susanna Longo, Marco Ciotti, and Sergio Bernardini. Evaluation of gfap/uch-l1 biomarkers for computed tomography exclusion in mild traumatic brain injury (mtbi). International Journal of Emergency Medicine, Oct 2024. URL: https://doi.org/10.1186/s12245-024-00708-z, doi:10.1186/s12245-024-00708-z. This article has 22 citations and is from a peer-reviewed journal.

  6. (giacino2012placebocontrolledtrialof pages 1-2): Joseph T. Giacino, John Whyte, Emilia Bagiella, Kathleen Kalmar, Nancy Childs, Allen Khademi, Bernd Eifert, David Long, Douglas I. Katz, Sooja Cho, Stuart A. Yablon, Marianne Luther, Flora M. Hammond, Annette Nordenbo, Paul Novak, Walt Mercer, Petra Maurer-Karattup, and Mark Sherer. Placebo-controlled trial of amantadine for severe traumatic brain injury. New England Journal of Medicine, 366:819-826, Mar 2012. URL: https://doi.org/10.1056/nejmoa1102609, doi:10.1056/nejmoa1102609. This article has 1023 citations and is from a highest quality peer-reviewed journal.

  7. (hutchinson2016trialofdecompressive pages 1-2): Peter J. Hutchinson, Angelos G. Kolias, Ivan S. Timofeev, Elizabeth A. Corteen, Marek Czosnyka, Jake Timothy, Ian Anderson, Diederik O. Bulters, Antonio Belli, C. Andrew Eynon, John Wadley, A. David Mendelow, Patrick M. Mitchell, Mark H. Wilson, Giles Critchley, Juan Sahuquillo, Andreas Unterberg, Franco Servadei, Graham M. Teasdale, John D. Pickard, David K. Menon, Gordon D. Murray, and Peter J. Kirkpatrick. Trial of decompressive craniectomy for traumatic intracranial hypertension. New England Journal of Medicine, 375:1119-1130, Sep 2016. URL: https://doi.org/10.1056/nejmoa1605215, doi:10.1056/nejmoa1605215. This article has 1645 citations and is from a highest quality peer-reviewed journal.

  8. (lipsky2024traumaticbraininjury pages 2-3): Robert H. Lipsky, Jeffrey M. Witkin, Hana Shafique, Jodi L. Smith, Rok Cerne, and Ann M. Marini. Traumatic brain injury: molecular biomarkers, genetics, secondary consequences, and medical management. Frontiers in Neuroscience, Oct 2024. URL: https://doi.org/10.3389/fnins.2024.1446076, doi:10.3389/fnins.2024.1446076. This article has 17 citations and is from a peer-reviewed journal.

  9. (lipsky2024traumaticbraininjury pages 3-4): Robert H. Lipsky, Jeffrey M. Witkin, Hana Shafique, Jodi L. Smith, Rok Cerne, and Ann M. Marini. Traumatic brain injury: molecular biomarkers, genetics, secondary consequences, and medical management. Frontiers in Neuroscience, Oct 2024. URL: https://doi.org/10.3389/fnins.2024.1446076, doi:10.3389/fnins.2024.1446076. This article has 17 citations and is from a peer-reviewed journal.

  10. (jha2024asinglecellatlas pages 3-5): Ruchira M. Jha, Dhivyaa Rajasundaram, Chaim Sneiderman, Brent T. Schlegel, Casey O’Brien, Zujian Xiong, Keri Janesko-Feldman, Ria Trivedi, Vincent Vagni, Benjamin E. Zusman, Joshua S. Catapano, Adam Eberle, Shashvat M. Desai, Ashutosh P. Jadhav, Sandra Mihaljevic, Margaux Miller, Sudhanshu Raikwar, Anupama Rani, Jarrod Rulney, Shima Shahjouie, Itay Raphael, Aditya Kumar, Chia-Ling Phuah, Ethan A. Winkler, Dennis W. Simon, Patrick M. Kochanek, and Gary Kohanbash. A single-cell atlas deconstructs heterogeneity across multiple models in murine traumatic brain injury and identifies novel cell-specific targets. Sep 2024. URL: https://doi.org/10.1016/j.neuron.2024.06.021, doi:10.1016/j.neuron.2024.06.021. This article has 84 citations and is from a highest quality peer-reviewed journal.

  11. (yan2024clinicalmanagementin pages 1-2): Amy Yan, Andrew Torpey, Erin Morrisroe, Wesam Andraous, Ana Costa, and Sergio D. Bergese. Clinical management in traumatic brain injury. Biomedicines, 12:781, Apr 2024. URL: https://doi.org/10.3390/biomedicines12040781, doi:10.3390/biomedicines12040781. This article has 53 citations.

  12. (manley2025anewcharacterisation pages 1-4): Geoffrey T Manley, Kristen Dams-O’Connor, Michael L Alosco, Hibah O Awwad, Jeffery J Bazarian, Peter Bragge, John D Corrigan, Adele Doperalski, Adam R Ferguson, Christine L Mac Donald, David K Menon, Molly M McNett, Joukje van der Naalt, Lindsay D Nelson, Dana Pisică, Noah D Silverberg, Nsini Umoh, Lindsay Wilson, Esther L Yuh, Henrik Zetterberg, Andrew I R Maas, Michael A McCrea, Rachel Syako Adams, Jennifer S Albrecht, David B Arciniegas, Breton M Asken, Ernest J Barthelemy, Mark Bayley, Thomas J Bayuk, Patrick Bellgowan, Shubhayu Bhattacharyay, Tricia Booker, David L Brody, Andras Buki, Heather Cameron, Lindsay Caron Epstein, Todd Cesar, Scott A Cota, Jill Daugherty, John Del Cecato, Bradley A Dengler, Ramon Diaz-Arrastia, Alicia Diggs, Maureen Dobbins, Ann-Christine Duhaime, Brian L Edlow, Ari Ercole, Anthony Figaji, Sarah N Fontaine, Guoyi Gao, Raquel C Gardner, Jessica Gill, Christopher C Giza, Juliet Haarbauer-Krupa, Scott Hamilton, Sidney Hinds, Lyn Jakeman, Shannon B Juengst, Inga K Koerte, Frederick K Korley, Walter Koroshetz, Rachel Lazarus, Fiona Lecky, Anthony H Lequerica, Lucia M Li, Rebekah Mannix, Stephanie Maxfield Panker, Andrew R Mayer, Gary McKinney, Timothy B Meier, Ana Mikolic, ACate Miller, Stefania Mondello, Kasey E Moritz, Pratik Mukherjee, Risa Nakase-Richardson, Virginia F J Newcombe, David O Okonkwo, Linda Papa, Monique R Pappadis, Corrine Peek-Asa, JB Phillips, Jennie Ponsford, Jussi P Posti, Ava M Puccio, Claudia S Roberston, Maya Sapiurka, Lindsay Simpson, Stephanie Sloley, Ewout Steyerberg, James Sulzer, Dwayne L Taliaferro, Olli Tenovuo, Danny G Thomas, Charlene Thomas, Abel Torres-Espin, Spyridoula Tsetsou, Alexis F Turgeon, Nancy Tuvesson, Eve Valera, Thijs Vande Vyvere, Claudio Villalobos Dintrans, Kevin K Wang, Melanie Wienhoven, Elisabeth A Wilde, Yu-Chien Wu, Keith Owen Yeates, John K Yue, and Deborah Yurgelun-Todd. A new characterisation of acute traumatic brain injury: the nih-ninds tbi classification and nomenclature initiative. The Lancet Neurology, 24:512-523, Jun 2025. URL: https://doi.org/10.1016/s1474-4422(25)00154-1, doi:10.1016/s1474-4422(25)00154-1. This article has 238 citations and is from a highest quality peer-reviewed journal.

  13. (valente2023clinicalpolicycritical pages 2-4): Jonathan H. Valente, John D. Anderson, William F. Paolo, Kelly Sarmiento, Christian A. Tomaszewski, Jason S. Haukoos, Deborah B. Diercks, Deborah B. Diercks, John D. Anderson, Richard Byyny, Christopher R. Carpenter, Benjamin Friedman, Seth R. Gemme, Charles J. Gerardo, Steven A. Godwin, Sigrid A. Hahn, Benjamin W. Hatten, Jason S. Haukoos, Amy Kaji, Heemun Kwok, Bruce M. Lo, Sharon E. Mace, Maggie Moran, Susan B. Promes, Kaushal H. Shah, Richard D. Shih, Scott M. Silvers, Andrea Slivinski, Michael D. Smith, Molly E.W. Thiessen, Christian A. Tomaszewski, Stacy Trent, Jonathan H. Valente, Stephen P. Wall, Lauren M. Westafer, Yanling Yu, Stephen V. Cantrill, John T. Finnell, Travis Schulz, and Kaeli Vandertulip. Clinical policy: critical issues in the management of adult patients presenting to the emergency department with mild traumatic brain injury: approved by acep board of directors, february 1, 2023 clinical policy endorsed by the emergency nurses association (april 5, 2023). Annals of emergency medicine, 81 5:e63-e105, May 2023. URL: https://doi.org/10.1016/j.annemergmed.2023.01.014, doi:10.1016/j.annemergmed.2023.01.014. This article has 12 citations and is from a domain leading peer-reviewed journal.

  14. (halabi2024traumaticbraininjury pages 1-2): Cathra Halabi, Saef Izzy, Anthony M. DiGiorgio, Hunter Mills, Farid Radmanesh, John K. Yue, Habibeh Ashouri Choshali, Gundolf Schenk, Sharat Israni, Ross Zafonte, and Geoffrey T. Manley. Traumatic brain injury and risk of incident comorbidities. JAMA Network Open, 7:e2450499, Dec 2024. URL: https://doi.org/10.1001/jamanetworkopen.2024.50499, doi:10.1001/jamanetworkopen.2024.50499. This article has 34 citations and is from a peer-reviewed journal.

  15. (cheng2025interactionsbetweenmild pages 17-20): Michael Cheng, Melody Mao, Wenjing Meng, Florin Vaida, Joanna Jacobus, Emily A Troyer, Everett L. Delfel, Emily L. Dennis, Elisabeth A Wilde, Tracy Abildskov, Nicola L. de Souza, Jeffrey E. Max, and Xia Yang. Interactions between mild traumatic brain injury and genetics perturb neuronal and glial pathways and networks relevant to learning and memory in abcd study. MedRxiv, Mar 2025. URL: https://doi.org/10.1101/2025.03.11.25323465, doi:10.1101/2025.03.11.25323465. This article has 0 citations.

  16. (patricios2023consensusstatementon pages 1-2): Jon S Patricios, Kathryn J Schneider, Jiri Dvorak, Osman Hassan Ahmed, Cheri Blauwet, Robert C Cantu, Gavin A Davis, Ruben J Echemendia, Michael Makdissi, Michael McNamee, Steven Broglio, Carolyn A Emery, Nina Feddermann-Demont, Gordon Ward Fuller, Christopher C Giza, Kevin M Guskiewicz, Brian Hainline, Grant L Iverson, Jeffrey S Kutcher, John J Leddy, David Maddocks, Geoff Manley, Michael McCrea, Laura K Purcell, Margot Putukian, Haruhiko Sato, Markku P Tuominen, Michael Turner, Keith Owen Yeates, Stanley A Herring, and Willem Meeuwisse. Consensus statement on concussion in sport: the 6th international conference on concussion in sport–amsterdam, october 2022. British Journal of Sports Medicine, 57:695-711, Jun 2023. URL: https://doi.org/10.1136/bjsports-2023-106898, doi:10.1136/bjsports-2023-106898. This article has 1660 citations and is from a highest quality peer-reviewed journal.

  17. (patricios2023consensusstatementon pages 5-6): Jon S Patricios, Kathryn J Schneider, Jiri Dvorak, Osman Hassan Ahmed, Cheri Blauwet, Robert C Cantu, Gavin A Davis, Ruben J Echemendia, Michael Makdissi, Michael McNamee, Steven Broglio, Carolyn A Emery, Nina Feddermann-Demont, Gordon Ward Fuller, Christopher C Giza, Kevin M Guskiewicz, Brian Hainline, Grant L Iverson, Jeffrey S Kutcher, John J Leddy, David Maddocks, Geoff Manley, Michael McCrea, Laura K Purcell, Margot Putukian, Haruhiko Sato, Markku P Tuominen, Michael Turner, Keith Owen Yeates, Stanley A Herring, and Willem Meeuwisse. Consensus statement on concussion in sport: the 6th international conference on concussion in sport–amsterdam, october 2022. British Journal of Sports Medicine, 57:695-711, Jun 2023. URL: https://doi.org/10.1136/bjsports-2023-106898, doi:10.1136/bjsports-2023-106898. This article has 1660 citations and is from a highest quality peer-reviewed journal.

  18. (valente2023clinicalpolicycritical pages 11-13): Jonathan H. Valente, John D. Anderson, William F. Paolo, Kelly Sarmiento, Christian A. Tomaszewski, Jason S. Haukoos, Deborah B. Diercks, Deborah B. Diercks, John D. Anderson, Richard Byyny, Christopher R. Carpenter, Benjamin Friedman, Seth R. Gemme, Charles J. Gerardo, Steven A. Godwin, Sigrid A. Hahn, Benjamin W. Hatten, Jason S. Haukoos, Amy Kaji, Heemun Kwok, Bruce M. Lo, Sharon E. Mace, Maggie Moran, Susan B. Promes, Kaushal H. Shah, Richard D. Shih, Scott M. Silvers, Andrea Slivinski, Michael D. Smith, Molly E.W. Thiessen, Christian A. Tomaszewski, Stacy Trent, Jonathan H. Valente, Stephen P. Wall, Lauren M. Westafer, Yanling Yu, Stephen V. Cantrill, John T. Finnell, Travis Schulz, and Kaeli Vandertulip. Clinical policy: critical issues in the management of adult patients presenting to the emergency department with mild traumatic brain injury: approved by acep board of directors, february 1, 2023 clinical policy endorsed by the emergency nurses association (april 5, 2023). Annals of emergency medicine, 81 5:e63-e105, May 2023. URL: https://doi.org/10.1016/j.annemergmed.2023.01.014, doi:10.1016/j.annemergmed.2023.01.014. This article has 12 citations and is from a domain leading peer-reviewed journal.

  19. (lipsky2024traumaticbraininjury pages 1-2): Robert H. Lipsky, Jeffrey M. Witkin, Hana Shafique, Jodi L. Smith, Rok Cerne, and Ann M. Marini. Traumatic brain injury: molecular biomarkers, genetics, secondary consequences, and medical management. Frontiers in Neuroscience, Oct 2024. URL: https://doi.org/10.3389/fnins.2024.1446076, doi:10.3389/fnins.2024.1446076. This article has 17 citations and is from a peer-reviewed journal.

  20. (brett2023longtermmultidomainpatterns pages 1-2): Benjamin L. Brett, Nancy Temkin, Jason K. Barber, David O. Okonkwo, Murray Stein, Yelena G. Bodien, John Corrigan, Ramon Diaz-Arrastia, Joseph T. Giacino, Michael A. McCrea, Geoffrey T. Manley, and Lindsay D. Nelson. Long-term multidomain patterns of change after traumatic brain injury. Neurology, Aug 2023. URL: https://doi.org/10.1212/wnl.0000000000207501, doi:10.1212/wnl.0000000000207501. This article has 66 citations and is from a highest quality peer-reviewed journal.

  21. (lotze2024poloxamer188exerts pages 1-5): Felicia P. Lotze and Matthias L. Riess. Poloxamer 188 exerts direct protective effects on mouse brain microvascular endothelial cells in an in vitro traumatic brain injury model. Biomedicines, 9:1043, Aug 2024. URL: https://doi.org/10.3390/biomedicines9081043, doi:10.3390/biomedicines9081043. This article has 13 citations.

  22. (brenner2020understandingtheneuroprotective pages 1-2): Amy Brenner, Antonio Belli, Rizwana Chaudhri, Timothy Coats, Lauren Frimley, Sabariah Faizah Jamaluddin, Rashid Jooma, Raoul Mansukhani, Peter Sandercock, Haleema Shakur-Still, Temitayo Shokunbi, and Ian Roberts. Understanding the neuroprotective effect of tranexamic acid: an exploratory analysis of the crash-3 randomised trial. Critical Care, Nov 2020. URL: https://doi.org/10.1186/s13054-020-03243-4, doi:10.1186/s13054-020-03243-4. This article has 48 citations and is from a highest quality peer-reviewed journal.

  23. (maity2024mappingdynamicmolecular pages 1-2): Sudipa Maity, Yuanyu Huang, Mitchell D. Kilgore, Abbigail N. Thurmon, Lee O. Vaasjo, Maria J. Galazo, Xiaojiang Xu, Jing Cao, Xiaoying Wang, Bo Ning, Ning Liu, and Jia Fan. Mapping dynamic molecular changes in hippocampal subregions after traumatic brain injury through spatial proteomics. Clinical Proteomics, May 2024. URL: https://doi.org/10.1186/s12014-024-09485-6, doi:10.1186/s12014-024-09485-6. This article has 20 citations and is from a peer-reviewed journal.

  24. (maity2024mappingdynamicmolecular pages 5-8): Sudipa Maity, Yuanyu Huang, Mitchell D. Kilgore, Abbigail N. Thurmon, Lee O. Vaasjo, Maria J. Galazo, Xiaojiang Xu, Jing Cao, Xiaoying Wang, Bo Ning, Ning Liu, and Jia Fan. Mapping dynamic molecular changes in hippocampal subregions after traumatic brain injury through spatial proteomics. Clinical Proteomics, May 2024. URL: https://doi.org/10.1186/s12014-024-09485-6, doi:10.1186/s12014-024-09485-6. This article has 20 citations and is from a peer-reviewed journal.

  25. (maity2024mappingdynamicmolecular media 666596e2): Sudipa Maity, Yuanyu Huang, Mitchell D. Kilgore, Abbigail N. Thurmon, Lee O. Vaasjo, Maria J. Galazo, Xiaojiang Xu, Jing Cao, Xiaoying Wang, Bo Ning, Ning Liu, and Jia Fan. Mapping dynamic molecular changes in hippocampal subregions after traumatic brain injury through spatial proteomics. Clinical Proteomics, May 2024. URL: https://doi.org/10.1186/s12014-024-09485-6, doi:10.1186/s12014-024-09485-6. This article has 20 citations and is from a peer-reviewed journal.

  26. (yan2025globalregionaland pages 1-2): Junqing Yan, Chao Wang, and Bangqing Sun. Global, regional, and national burdens of traumatic brain injury from 1990 to 2021. Frontiers in Public Health, Apr 2025. URL: https://doi.org/10.3389/fpubh.2025.1556147, doi:10.3389/fpubh.2025.1556147. This article has 112 citations.

  27. (patricios2023consensusstatementon pages 6-7): Jon S Patricios, Kathryn J Schneider, Jiri Dvorak, Osman Hassan Ahmed, Cheri Blauwet, Robert C Cantu, Gavin A Davis, Ruben J Echemendia, Michael Makdissi, Michael McNamee, Steven Broglio, Carolyn A Emery, Nina Feddermann-Demont, Gordon Ward Fuller, Christopher C Giza, Kevin M Guskiewicz, Brian Hainline, Grant L Iverson, Jeffrey S Kutcher, John J Leddy, David Maddocks, Geoff Manley, Michael McCrea, Laura K Purcell, Margot Putukian, Haruhiko Sato, Markku P Tuominen, Michael Turner, Keith Owen Yeates, Stanley A Herring, and Willem Meeuwisse. Consensus statement on concussion in sport: the 6th international conference on concussion in sport–amsterdam, october 2022. British Journal of Sports Medicine, 57:695-711, Jun 2023. URL: https://doi.org/10.1136/bjsports-2023-106898, doi:10.1136/bjsports-2023-106898. This article has 1660 citations and is from a highest quality peer-reviewed journal.

  28. (sperry2024earlygfapand pages 1-2): Jason L. Sperry, James F. Luther, David O. Okonkwo, Laura E. Vincent, Vikas Agarwal, Bryan A. Cotton, Jeremy W. Cannon, Martin A. Schreiber, Ernest E. Moore, Nicholas Namias, Joseph P. Minei, Kelly L. Urbanek, Mark H. Yazer, Ava M. Puccio, Erin E. Fox, Joshua B. Brown, Matthew D. Neal, Frank X. Guyette, Stephen R. Wisniewski, _ , Barbara J. Early-Young, Meghan L. Buck, Peter W. Adams, Rachel L. Molinaro, Alexandra Merti, Ashely M. Harner, Elizabeth A. Gimbel, Logan Owens, Hannah Hayes, Alan Jackson, Laurie Silfies, Lisa Over, Steve Knopf, Melody Macey-Kalcevic, Angela Pattison, Megan E. Buhay, Brianna J. Higginbottom, Marissa L. Marcin, _ , _ _, Cara Battistella, Yu Bai, Kandice L. Motley, Yao-Wei Wang, Victoria Herrick, Garrett Woodruff, Veda Pa, Rhonda Hobbs, Jeanette Podbielski, Laura Vincent, Christy Allen, Subin Alexander, Natolie Hamilton, Symantha Lopez, Selina Hernandez Gonzalez, Jason Rashall, James Seymour, Nicole Zarate, Alea Zone, Sarah Joergensen, Liam Forsythe, Daria Zaitseva, Paul Callahan, Komal Khan, Olivia Doran, Sarah Gamblin, Lydia Fisher, Daniela Schmulevich, Steve Balian, Carrie Diamond, Jonathan Kolansky, Dena Torrente, Sean Van Walchren, Diane Lape, Angela Sauaia, Jason Haukoos, Lee Anne Ammons, James Chandler, Marcela Fitzpatrick, Emmalee Vittatoe, Nick Brant, Stephanie Kennedy, Megan Swope, Ronald Manning, Cristina Botero Fonnegra, Sebastian Brito, Vivian Calderon, Majid Chammas, Anthony Dure, Chelsea Ferreira, Allison Ferreira, Richard Guerra, Ivonne Guzman, Aaliyah Jolly, Rajan Ramdev, Shreedhar Reddy, and Nadia Nassaj. Early gfap and uch-l1 point-of-care biomarker measurements for the prediction of traumatic brain injury and progression in patients with polytrauma and hemorrhagic shock. Journal of Neurosurgery, 141(4):917-926, Oct 2024. URL: https://doi.org/10.3171/2024.1.jns232569, doi:10.3171/2024.1.jns232569. This article has 26 citations and is from a domain leading peer-reviewed journal.

  29. (pyne2024costeffectivenessofcraniotomy pages 1-2): Sarah Pyne, Garry Barton, David Turner, Harry Mee, Barbara A Gregson, Angelos G Kolias, Carole Turner, Hadie Adams, Midhun Mohan, Christopher Uff, Shumaila Hasan, Mark Wilson, Diederik Oliver Bulters, Ardalan Zolnourian, Catherine McMahon, Matthew G Stovell, Yahia Al-Tamimi, Simon Thomson, Edoardo Viaroli, Antonio Belli, Andrew King, Adel E Helmy, Ivan Timofeev, David Menon, and Peter John Hutchinson. Cost-effectiveness of craniotomy versus decompressive craniectomy for uk patients with traumatic acute subdural haematoma. Jun 2024. URL: https://doi.org/10.1136/bmjopen-2024-085084, doi:10.1136/bmjopen-2024-085084. This article has 10 citations and is from a peer-reviewed journal.

  30. (NCT06253923 chunk 1): Study to Assess the Safety of Amantadine Hydrochloride (HCl) Intravenous (IV) Solution (MR-301) in Patients With Severe Traumatic Brain Injury (TBI).. SHINKEI Therapeutics, Inc. 2024. ClinicalTrials.gov Identifier: NCT06253923

  31. (NCT02407028 chunk 1): Gaylan Rockswold. Hyperbaric Oxygen Brain Injury Treatment Trial. Gaylan Rockswold. 2018. ClinicalTrials.gov Identifier: NCT02407028

  32. (vetere2024casereportevaluation pages 1-2): Alessandro Vetere, Nicola Della Camera, Ciro Cococcetta, Carlo Paoletti, Maurizio Dondi, Fabio Biaggi, and Francesco Di Ianni. Case report: evaluation of head trauma in a tawny owl (strix aluco) with advanced imaging diagnostic, fvep and baer test. Frontiers in Veterinary Science, Aug 2024. URL: https://doi.org/10.3389/fvets.2024.1439432, doi:10.3389/fvets.2024.1439432. This article has 1 citations and is from a peer-reviewed journal.

  33. (hall2024breakingbarriersin pages 1-2): Kelly E. Hall, Claire Tucker, Julie A. Dunn, Tracy Webb, Sarah A. Watts, Emrys Kirkman, Julien Guillaumin, Guillaume L. Hoareau, and Heather F. Pidcoke. Breaking barriers in trauma research: a narrative review of opportunities to leverage veterinary trauma for accelerated translation to clinical solutions for pets and people. Journal of Clinical and Translational Science, Apr 2024. URL: https://doi.org/10.1017/cts.2024.513, doi:10.1017/cts.2024.513. This article has 0 citations.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.3.0rc3.

Outcome Count
References checked 29
Resolved 28
Unresolved (possible confabulation) 0
Unverifiable 1
References weighed for topical relevance 28
On topic 8
Off topic 0

28 of 29 references resolved; the rest could not be looked up either way.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 1
Resolved 1
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 0
Terms whose name was checked 1
Terms named correctly 0
Terms named as a different term 1

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • MONDO:0858950 (2 mentions) - the report calls it "if available"; MONDO calls it traumatic brain injury